

CITATION REPORT

List of articles citing

The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study

DOI: 10.1016/j.amjcard.2004.12.032

American Journal of Cardiology, 2005, 95, 948-54.

Source: <https://exaly.com/paper-pdf/38266942/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
987	Combined use of amino terminal-pro-brain natriuretic peptide levels and QRS duration to predict left ventricular systolic dysfunction in patients with dyspnea. <i>American Journal of Cardiology</i> , 2005 , 96, 263-6	3	12
986	Laboratory testing for B-type natriuretic peptides (BNP and NT-proBNP): clinical usefulness, utilization, and impact on hospital operations. 2005 , 124 Suppl, S122-8		2
985	Does this dyspneic patient in the emergency department have congestive heart failure?. 2005 , 294, 1944-56		364
984	Acutely decompensated congestive heart failure: new therapies for an old problem. 2005 , 3, 925-36		
983	Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. 2006 , 92, 843-9		300
982	N-terminal proBNP: a novel biomarker for the diagnosis, risk stratification and management of congestive heart failure. 2005 , 3, 487-96		4
981	Role of N-terminal pro-B-type natriuretic peptide in risk stratification in patients presenting in the emergency room. 2005 , 51, 1624-31		25
980	NTproBNP circulante, un nuevo biomarcador para el diagnóstico del paciente con disnea aguda. 2005 , 58, 1142-1144		11
979	The Circulating NTproBNP Level, a New Biomarker for the Diagnosis of Heart Failure in Patients With Acute Shortness of Breath. 2005 , 58, 1142-1144		
978	The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. 2005 , 11, S9-14		88
977	Overcoming gaps in the management of asthma in older patients: new insights. 2005 , 22, 1029-59		34
976	Intérêt des marqueurs biologiques en cas de dyspnée aiguë 2006 , 10, 263-269		
975	EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. 2006 , 27, 2725-36		825
974	NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. 2006 , 27, 330-7		786
973	Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. 2006 , 22, 23-45		323
972	Natriuretic peptides as diagnostic test: lessons from the first 5 years of clinical application. 2006 , 2, 299-309		4
971	Plasma BNP/NT-proBNP assays: what do they target and what else might they recognize?. 2006 , 2, 291-8		4

970	Natriuretic peptides and renal insufficiency: clinical significance and role of renal clearance. 2006 , 2, 277-90	3
969	Multicentre evaluation of a new point-of-care test for the determination of NT-proBNP in whole blood. 2006 , 44, 1269-77	20
968	Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. 2006 , 47, 91-7	284
967	The coming of age of natriuretic peptides: the emperor does have clothes!. 2006 , 47, 61-4	33
966	Biomarkers in acute cardiac disease: the present and the future. 2006 , 48, 1-11	1092
965	Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. 2006 , 48, 1217-24	427
964	Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction?. 2006 , 48, 1621-7	115
963	Evaluation of patients for ventricular dysfunction and heart failure. 2006 , 12, e16-25	6
962	Evaluation and management of patients with acute decompensated heart failure. 2006 , 12, e86-e103	54
961	Neither race nor gender influences the usefulness of amino-terminal pro-brain natriuretic peptide testing in dyspneic subjects: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. 2006 , 12, 452-7	36
960	Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: a prospective cohort study. 2006 , 10, R37	61
959	Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. 2006 , 152, 828-34	130
958	A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score. 2006 , 151, 48-54	45
957	Management of elderly patients with congestive heart failure--design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). 2006 , 151, 949-55	86
956	Population-based detection of systolic and diastolic dysfunction with amino-terminal pro-B-type natriuretic peptide. 2006 , 152, 941-8	49
955	B-type natriuretic peptide and amino terminal proBNP predict one-year mortality in short of breath patients independently of the baseline diagnosis of acute destabilized heart failure. 2006 , 370, 174-9	36
954	[Usefulness of B-type natriuretic peptide in emergency medicine]. 2006 , 27, 858-64	1
953	The Importance of Amino-terminal pro-Brain Natriuretic Peptide Testing in Clinical Cardiology. <i>Biomarker Insights</i> , 2006 , 1, 117727190600100	3.5 0

952	Should natriuretic peptide testing be incorporated into emergency medicine practice?. 2006 , 8, 259-61	5
951	Diagnostic usefulness of B-type natriuretic peptide and functional consequences of muscle alterations in COPD and chronic heart failure. 2006 , 130, 1220-30	7
950	Full Length Article. 2006 , 48, 1621-1627	110
949	Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. 2006 , 34, 2140-4	197
948	Cardiac Markers. 2006 , 5, 38-46	4
947	Update on Natriuretic Peptides. 2006 , 5, 6-12	1
946	Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. 2007 , 35, 1821-8	534
945	A review of the natriuretic hormone system's diagnostic and therapeutic potential in critically ill children. 2006 , 7, 308-18	40
944	B-type natriuretic peptide in heart failure. 2006 , 21, 208-14	42
943	Potential impact of N-terminal pro-BNP testing on the emergency department evaluation of acute dyspnea. 2006 , 8, 251-8	12
942	Potential value for new diagnostic markers in the early recognition of acute coronary syndromes. 2006 , 8, 27-31	67
941	Access to Annals of Emergency Medicine Online is now reserved for ACEP members and print subscribers. 2006 , 48, 76	
940	Clinical characteristics of emergency department heart failure patients initially diagnosed as non-heart failure. 2006 , 6, 11	10
939	B-type natriuretic peptide in the diagnosis of heart failure in the emergency department. 2006 , 18, 170-9	3
938	Amino-terminal pro-brain natriuretic peptide for the diagnosis of acute heart failure in patients with previous obstructive airway disease. 2006 , 48, 66-74	25
937	Getting the right message: avoiding overly optimistic interpretations of the scientific literature. 2006 , 48, 75-6	1
936	Kortademigheid bij ouderen. 2006 , 22, 347-350	
935	[Differential diagnosis of dyspnea - significance of clinic aspects, imaging and biomarkers for the diagnosis of heart failure]. <i>Clinical Research in Cardiology</i> , 2006 , 95 Suppl 4, 57-70; quiz 71	6.1 14

934	[Acute heart failure: rational diagnostics in clinical practice and the emergency department]. 2006 , 31, 736-47		3
933	Cost effectiveness of natriuretic peptide measurement in the primary care setting: have we found the gatekeeper for the evaluation of dyspneic outpatients?. 2006 , 12, 108-9		
932	N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. <i>American Journal of Cardiology</i> , 2006 , 97, 1530-4	3	77
931	Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. <i>American Journal of Cardiology</i> , 2006 , 98, 386-90	3	84
930	Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. <i>American Journal of Cardiology</i> , 2006 , 98, 800-5	3	69
929	NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. 2006 , 27, 839-45		110
928	Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. 2007 , 28, 177-82		52
927	Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. 2006 , 166, 315-20		180
926	Amino-terminal pro-brain natriuretic peptide: a biomarker for diagnosis, prognosis and management of heart failure. 2006 , 6, 649-62		4
925	Natriuretic peptides in the diagnosis and management of heart failure. 2006 , 175, 611-7		71
924	Natriuretic peptides: diagnostic tools and predictors of heart failure outcome. 2006 , 2, 667-76		
923	B-type natriuretic peptides as powerful markers in cardiac diseases [Analytical and clinical aspects / B-Typ natriuretische Peptide als aussagekräftige Marker bei kardialen Erkrankungen [Analytische und klinische Aspekte. 2006 , 30, 165-184		
922	Elevation of myeloperoxidase in conjunction with cardiac-specific markers after marathon running. 2006 , 126, 888-93		28
921	Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers. 2006 , 174, 990-6		94
920	Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP. 2006 , 52, 827-31		84
919	Diffraction optics technology: a novel detection technology for immunoassays. 2006 , 52, 2168-72		20
918	Raised plasma N-terminal pro-B-type natriuretic peptide concentrations predict mortality and cardiac disease in end-stage renal disease. 2006 , 92, 1518-9		15
917	B-type natriuretic peptides as powerful markers in cardiac diseases: Analytical and clinical aspects. 2006 , 25, 287-308		

916	High diagnostic accuracy of NT-proBNP for cardiac origin of pleural effusions. 2006 , 28, 144-50		50
915	Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. 2006 , 126, 506-12		93
914	A magnetic immunochromatographic strip test for detection of human papillomavirus 16 E6. 2006 , 52, 2170-2		31
913	Comparison of brain natriuretic peptide (BNP) and amino-terminal ProBNP for early diagnosis of heart failure. 2007 , 53, 1289-97		64
912	Value of BNP to estimate cardiac risk in patients on cardioactive treatment in primary care. <i>European Journal of Heart Failure</i> , 2007 , 9, 1178-85	12.3	10
911	Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. <i>European Journal of Heart Failure</i> , 2007 , 9, 68-74	12.3	70
910	Clinical trials update from the American Heart Association 2006: OAT, SALT 1 and 2, MAGIC, ABCD, PABA-CHF, IMPROVE-CHF, and percutaneous mitral annuloplasty. <i>European Journal of Heart Failure</i> , 2007 , 9, 92-7	12.3	27
909	B-type natriuretic peptides in heart failure: update on clinical applications and limitations. 2007 , 1, 503-12		2
908	N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. 2007 , 115, 3103-10		251
907	Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. 2007 , 53, 1511-9		79
906	Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARE-CHD Registry. 2007 , 100, 1234-41		187
905	Amino-terminal pro-brain natriuretic peptide, brain natriuretic peptide, and troponin T for prediction of mortality in acute heart failure. 2007 , 53, 412-20		36
904	Analytical and clinical performance of three natriuretic peptide tests in the emergency room. 2007 , 45, 678-84		16
903	Neurohumoral activity, heart failure and prognosis in patients with end-stage renal disease treated by hemodialysis. 2007 , 30, 347-57		4
902	Biomarkers of cardiovascular damage. 2007 , 16, 247-61		32
901	Can we IMPROVE-CHF management by measuring natriuretic peptides?. 2007 , 115, 3045-7		2
900	Clinical approaches to the diagnosis of acute heart failure. 2007 , 22, 207-13		13
899	BNP can help rapidly diagnose HF. 2007 , 2, 7		

898 Laboratory and diagnostic testing: a perioperative update. **2007**, 85, 754-62; quiz 763-6

897 NT-proBNP in chronic hypercapnic respiratory failure: a marker of disease severity, treatment effect and prognosis. *Respiratory Medicine*, **2007**, 101, 2003-10 4.6 16

896 Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. **2007**, 153, 90-7 64

895 Highlights from the 20th Scientific Sessions of the American Heart Association: November 12 to 15, 2006, Chicago, Illinois. **2007**, 153, 213-223 1

894 Hemoglobin and N-terminal pro-brain natriuretic peptide: Independent and synergistic predictors of mortality in patients with acute heart failure Results from the International Collaborative of NT-proBNP (ICON) Study. **2007**, 381, 145-50 32

893 False-positive BNP results in a 78-year-old man caused by monoclonal IgM-kappa: a case report. **2007**, 384, 179 3

892 Multi-center validation of the Response Biomedical Corporation RAMP NT-proBNP assay with comparison to the Roche Diagnostics GmbH Elecsys proBNP assay. **2007**, 386, 20-4 20

891 Head-to-head comparison of BNP and IL-6 as markers of clinical and experimental heart failure: Superiority of BNP. **2007**, 40, 89-97 24

890 Prognosis of decompensated heart failure patients with preserved systolic function is predicted by NT-proBNP variations during hospitalization. *International Journal of Cardiology*, **2007**, 117, 75-9 3.2 23

889 Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure. *International Journal of Cardiology*, **2007**, 120, 338-43 3.2 27

888 Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. **2007**, 23, 21-45 110

887 Evaluating the role of biomarkers for cardiovascular risk prediction: focus on CRP, BNP and urinary microalbumin. **2007**, 7, 793-804 22

886 National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. **2007**, 116, e99-109 186

885 Evaluation of the acutely dyspneic elderly patient. **2007**, 23, 307-25, vi 30

884 [Measurement of NT-proBNP in elderly patients with acute dyspnea: diagnostic and pronostic value]. **2007**, 128, 453-5 1

883 Effects of ambient air pollution on functional status in patients with chronic congestive heart failure: a repeated-measures study. **2007**, 6, 26 21

882 Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. **2007**, 49, 1943-50 377

881 Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. **2007**, 50, 607-13 385

880	Biomarkers in heart failure. Does prognostic utility translate to clinical futility?. 2007 , 50, 1061-3		14
879	Natriuretic peptides. 2007 , 50, 2357-68		774
878	Basics of Natriuretic Peptides: Practical Aspects of Assays, Potential Analytical Confounders, and Clinical Interpretation. 128-133		
877	. 2007 ,		
876	Response to "Getting the right message". 2007 , 49, 381-3; discussion 383; author reply 384		2
875	Clinical policy: Critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes. 2007 , 49, 627-69		89
874	Cardiac asthma in elderly patients: incidence, clinical presentation and outcome. 2007 , 7, 16		37
873	Acute decompensated heart failure: pathophysiology and treatment. <i>American Journal of Cardiology</i> , 2007 , 99, 25D-30D	3	30
872	Usefulness of aminoterminal pro-brain natriuretic peptide testing for the diagnostic and prognostic evaluation of dyspneic patients with diabetes mellitus seen in the emergency department (from the PRIDE Study). <i>American Journal of Cardiology</i> , 2007 , 100, 1336-40	3	18
871	B-type natriuretic peptide: a critical review. 2007 , 13, 48-52		14
870	Recent advances in natriuretic peptide research. 2007 , 11, 1263-71		33
869	B-type natriuretic peptide as a marker for heart failure in patients with acute stroke. 2007 , 33, 1587-93		30
868	Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. 2007 , 12, 23-36		77
867	NT-pro-BNP measured at discharge predicts outcome in multimorbid diabetic inpatients with a broad spectrum of cardiovascular disease. 2007 , 44, 91-7		10
866	The relationship between tissue Doppler imaging and seric NTproBNP levels in sinus rhythm patients: a prospective study. 2008 , 24, 399-407		7
865	Acute heart failure: new diagnostic perspectives for the emergency physician. 2008 , 3, 37-41		12
864	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. 2008 , 41, 210-21		53
863	B-type natriuretic peptides for the diagnosis of congestive heart failure in dyspneic oldest-old patients. 2008 , 41, 1049-54		11

862	N-terminal pro-brain natriuretic peptide in the elderly with myocardial infarction. 2008 , 31, 443-7		2
861	Biomarkers in heart failure. 2008 , 358, 2148-59		923
860	Accuracy of chest radiographs in the emergency diagnosis of heart failure. 2008 , 18, 1644-52		20
859	Prevalence and misdiagnosis of chronic heart failure in nursing home residents: the role of B-type natriuretic peptides. 2008 , 16, 123-8		36
858	Message in a bottle--natriuretic peptide determination as a noninvasive measurement of pulmonary capillary wedge pressure?. 2008 , 62, 177-8		
857	The IL-33/ST2 pathway: therapeutic target and novel biomarker. 2008 , 7, 827-40		496
856	Diagnostic value of pleural fluid N-terminal pro-brain natriuretic peptide levels in patients with cardiovascular diseases. 2008 , 13, 53-7		22
855	Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. 2008 , 38, 101-13		76
854	Prognostic merit of N-terminal-proBNP and N-terminal-proANP in mechanically ventilated critically ill patients. 2008 , 52, 1265-72		10
853	High NT-proBNP is a strong predictor of outcome in elderly heart failure patients. 2008 , 17, 13-20		17
852	Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. <i>American Journal of Cardiology</i> , 2008 , 101, 29-38	3	64
851	Importance and interpretation of intermediate (gray zone) amino-terminal pro-B-type natriuretic peptide concentrations. <i>American Journal of Cardiology</i> , 2008 , 101, 39-42	3	29
850	Amino-terminal pro-B-type natriuretic peptide testing and prognosis in patients with acute dyspnea, including those with acute heart failure. <i>American Journal of Cardiology</i> , 2008 , 101, 49-55	3	27
849	Amino-terminal pro-B-type natriuretic peptide testing in renal disease. <i>American Journal of Cardiology</i> , 2008 , 101, 82-8	3	72
848	The editor's roundtable: B-type natriuretic peptide. <i>American Journal of Cardiology</i> , 2008 , 101, 1733-40	3	5
847	Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. <i>American Journal of Cardiology</i> , 2008 , 102, 733-7	3	82
846	Cardiovascular Disease in Patients With Chronic Renal Impairment: Role of Natriuretic Peptides. 2008 , 14, 38-42		7
845	Cardiovascular disease in patients with chronic renal impairment: role of natriuretic peptides. 2008 , 14, 38-42		7

844	Brain natriuretic peptides as biomarkers for atherosclerosis. 2008 , 11, 172-6		9
843	Cardiac blood biomarkers in patients receiving thoracic (chemo)radiation. 2008 , 62, 351-5		36
842	Evaluation of circulating amino terminal-pro-B-type natriuretic peptide concentration in dogs with respiratory distress attributable to congestive heart failure or primary pulmonary disease. 2008 , 232, 1674-9		51
841	Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. 2008 , 52, 450-9		134
840	Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis. 2008 , 52, 534-40		156
839	Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. 2008 , 52, 1458-65		280
838	Acute Heart Failure. 2008 ,		7
837	Biomarker responses during mid-term mechanical cardiac support in children. 2008 , 27, 150-7		14
836	Diagnostic and prognostic impact of brain natriuretic peptide in cardiac and noncardiac diseases. 2008 , 37, 275-85		21
835	Lack of decrease in plasma N-terminal pro-brain natriuretic peptide identifies acute heart failure patients with very poor outcome. <i>International Journal of Cardiology</i> , 2008 , 129, 373-8	3.2	10
834	Use of B-type natriuretic peptide outside of the emergency department. <i>International Journal of Cardiology</i> , 2008 , 127, 5-16	3.2	32
833	BNP or NTproBNP? A clinician's perspective. <i>International Journal of Cardiology</i> , 2008 , 129, 5-14	3.2	45
832	Biomarkers for cardiovascular disease: challenges and future directions. 2008 , 14, 261-7		31
831	N-terminal pro-brain natriuretic peptide testing in the emergency department: beneficial effects on hospitalization, costs, and outcome. 2008 , 156, 71-7		38
830	N-Terminal pro B-type natriuretic peptide testing for short-term prognosis in breathless older adults. 2008 , 26, 555-60		9
829	Correlation between cardiac biomarkers and right ventricular enlargement on chest CT in non massive pulmonary embolism. 2008 , 121, 617-24		32
828	Analytical and clinical performance of the Ortho-Clinical Diagnostics VITROS amino-terminal pro-B type natriuretic peptide assay. 2008 , 387, 48-54		7
827	Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. 2008 , 392, 41-5		45

826	[Diagnostic usefulness of N-terminal brain natriuretic peptide in patients admitted to a cardiology service]. 2008 , 131, 737-8		0
825	[NT-proBNP for the diagnosis of acute heart failure: where are we now?]. 2008 , 131, 739-40		0
824	New cardiovascular risk markers: the race is on, but are there any winners?. 2008 , 68, 673-7		2
823	Ultrasound lung comets for the differential diagnosis of acute cardiogenic dyspnoea: a comparison with natriuretic peptides. <i>European Journal of Heart Failure</i> , 2008 , 10, 70-7	12.3	181
822	Bench-to-bedside review: the value of cardiac biomarkers in the intensive care patient. 2008 , 12, 215		18
821	Differential diagnosis of acute dyspnea: the value of B natriuretic peptides in the emergency department. 2008 , 101, 831-43		28
820	Natriuretic peptide testing in emergency settings. 2008 , 46, 1543-9		3
819	Error in Signature Block in: Successful Treatment of Adult Cerebral Salt Wasting With Fludrocortisone. 2008 , 168, 748		
818	Response to Letter Regarding Article, N-Terminal ProB-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure: Primary Results of the Canadian Prospective Randomized Multicenter IMPROVE-CHF Study□ 2008 , 117,		1
817	Commentary: how serious is getting a diagnosis of prostate cancer?. 2008 , 13, 306-8		
816	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: application of natriuretic peptides. 2009 , 30, 382-3; author reply 383		16
815	Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspnea. 2008 , 168, 741-8		72
814	Interventricular mechanical dyssynchrony determines abnormal heightening of plasma N-terminal probrain natriuretic peptide level in symptomatic bradyarrhythmia patients with chronic dual-chamber vs. single-chamber atrial pacing. 2008 , 110, 167-73		2
813	Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition. 2008 , 29, 413-21		35
812	A clinical and biochemical score for mortality prediction in patients with acute dyspnoea: derivation, validation and incorporation into a bedside programme. 2008 , 94, 1032-7		10
811	B-type natriuretic peptides: prognostic markers in stable coronary artery disease. 2008 , 8, 217-25		18
810	Review on natriuretic peptides: where we are, where we are going. 2008 , 2, 1137-53		1
809	Inflammatory markers, amino-terminal pro-brain natriuretic peptide, and mortality risk in dyspneic patients. 2008 , 130, 305-11		7

808	The diagnostic value of serum and urinary NT-proBNP for heart failure. 2008 , 45, 389-94		20
807	Use of cardiac biomarkers in end-stage renal disease. 2008 , 19, 1643-52		144
806	Exercise-induced biphasic increase in circulating NT-proBNP levels in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2008 , 10, 793-5	12.3	2
805	BNP and NT-proBNP predict echocardiographic severity of diastolic dysfunction. <i>European Journal of Heart Failure</i> , 2008 , 10, 252-9	12.3	77
804	Natriuretic peptides and their evolving clinical applications. 2008 , 4, 593-8		3
803	N-terminal pro-B-type natriuretic peptide concentrations predict the risk of cardiovascular adverse events from antiinflammatory drugs: a pilot trial. 2008 , 54, 1149-57		13
802	Some heterogeneity factors affecting the B-type natriuretic peptides outcome: a meta-analysis. 2008 , 46, 1687-95		3
801	Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease. 2008 , 130, 578-84		43
800	Natriuretic peptide levels: what's on the horizon?. 2008 , 4, 107-9		1
799	[Natriuretic peptides--when should they be used in heart failure?]. 2008 , 133, 196-200		1
798	Accuracy of N-terminal-pro-atrial natriuretic peptide in patients admitted to emergency department. 2008 , 68, 410-4		10
797	State of the art: using natriuretic peptide levels in clinical practice. <i>European Journal of Heart Failure</i> , 2008 , 10, 824-39	12.3	529
796	Society of Chest Pain Centers Recommendations for the evaluation and management of the observation stay acute heart failure patient: a report from the Society of Chest Pain Centers Acute Heart Failure Committee. 2008 , 7, 83-6		34
795	BNP can help rapidly diagnose HF. 2008 , 3, 5-9		
794	Acute Decompensated Heart Failure. 190-199		
793	Successful treatment of adult cerebral salt wasting with fludrocortisone. 2008 , 168, 325-6		16
792	Brain natriuretic peptide in cardiovascular diseases. <i>American Journal of the Medical Sciences</i> , 2008 , 335, 477-83	2.2	1
791	Use of Natriuretic Peptides in the Diagnosis of Heart Failure. 93-115		

790	Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure. 2008 , 36, S17-27	53
789	Biomarkers in acute cardiovascular disease. 2008 , 23, 124-31	28
788	Natriuretic peptide testing in clinical medicine. 2008 , 16, 240-9	21
787	Biomarkers in heart failure management. 2008 , 23, 127-33	11
786	Diagnosis. 2008 , 7, 91-95	
785	The use of natriuretic peptides in the intensive care unit. 2008 , 14, 536-42	2
784	Biomarkers in heart failure management. 2008 , 7, 226-232	
783	. 2008 ,	1
782	Usefulness of B Natriuretic Peptides and Procalcitonin in Emergency Medicine. <i>Biomarker Insights</i> , 2008 , 3, 203-217	3.5 7
781	New instruments to diagnose acute dyspnoea of cardiogenic origin. 2008 , 4, 36	
780	The Diagnostic Value of B Natriuretic Peptide in Elderly Patients with Acute Dyspnea. 2008 , 2, CMC.S525	
779	Does B-type natriuretic peptide testing affect outcome and management of patients with acute dyspnea?. 2009 , 151, 288-9; author reply 289-90	
778	Does B-type natriuretic Peptide testing affect outcome and management of patients with acute dyspnea?. 2009 , 151, 289; author reply 289-90	
777	Prognostic stratification of acute pulmonary embolism: focus on clinical aspects, imaging, and biomarkers. 2009 , 5, 567-75	44
776	Combination of quantitative capnometry, N-terminal pro-brain natriuretic peptide, and clinical assessment in differentiating acute heart failure from pulmonary disease as cause of acute dyspnea in pre-hospital emergency setting: study of diagnostic accuracy. 2009 , 50, 133-42	18
775	Comments on the recent clinical guidance statement on HIV screening. 2009 , 151, 286-7; author reply 287	
774	Society of Chest Pain Centers recommendations for the evaluation and management of the observation stay acute heart failure patient-parts 1-6. 2009 , 11, 3-42	37
773	Cardiorenal syndrome: biomarkers linking kidney damage with heart failure. 2009 , 3, 549-60	11

772	B-type natriuretic peptide (BNP)/NT-proBNP and renal function: is the controversy over?. 2009 , 55, 1271-3	18
771	Amino-terminal pro-B-type natriuretic peptide as predictor of mortality in patients with symptomatic peripheral arterial disease: 5-year follow-up data from the Linz Peripheral Arterial Disease Study. 2009 , 55, 68-77	29
770	Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. 2009 , 95, 1508-13	63
769	Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. 2009 , 88, 131-140	125
768	Estimation of split-points in binary regression. 2009 , 27,	3
767	Assessment of the presence of occult myocardial infarction in chronic obstructive pulmonary disease using contrast-enhanced cardiac magnetic resonance imaging. 2009 , 78, 263-9	4
766	Association between troponin T and impaired left ventricular relaxation in patients with acute decompensated heart failure with preserved systolic function. 2009 , 10, 765-8	23
765	Predicting future shocks in implantable cardioverter defibrillator recipients: the role of biomarkers. 2009 , 11, 1434-9	0
764	[Biomarkers in heart failure: are they clinically useful?]. 2009 , 134, 740-6	0
763	Use of B-type natriuretic peptide in critically ill patients. 2009 , 3, 541-7	11
762	Comparison of the cardiac markers B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide. 2009 , 3, 465-81	11
761	Biomarkers of risk stratification in congestive heart failure: North American view. 2009 , 3, 443-52	2
760	Natriuretic peptides and echocardiography in acute dyspnoea: implication of elevated levels with normal systolic function. <i>European Journal of Heart Failure</i> , 2009 , 11, 659-67	12.3 13
759	Effects of n-3 polyunsaturated fatty acid therapy on plasma inflammatory markers and N-terminal pro-brain natriuretic peptide in elderly patients with chronic heart failure. 2009 , 37, 1831-41	54
758	Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. <i>Circulation: Heart Failure</i> , 2009 , 2, 311-9	7.6 143
757	Lack of diagnostic and prognostic utility of circulating plasma myeloperoxidase concentrations in patients presenting with dyspnea. 2009 , 55, 59-67	25
756	Usefulness of natriuretic peptide testing for long-term risk assessment following acute ischemic stroke. <i>American Journal of Cardiology</i> , 2009 , 104, 287-91	3 24
755	[NT-proBNP in practice: from chemistry to medicine]. 2009 , 58, 165-79	5

754	Determinants of plasma NT-pro-BNP levels in patients with atrial fibrillation and preserved left ventricular ejection fraction. <i>Clinical Research in Cardiology</i> , 2009 , 98, 101-6	6.1	35
753	The evolution of the natriuretic peptides - Current applications in human and animal medicine. 2009 , 11 Suppl 1, S9-21		28
752	Cardiovascular and renal surrogate markers in the clinical management of hypertension. 2009 , 23, 317-26		11
751	Can plasma levels of N-terminal pro-brain natriuretic peptide be useful in predicting the risk of developing chronic pulmonary hypertension in patients with pulmonary embolism?. 2009 , 4, 443-4		
750	Response of novel biomarkers to BNP infusion in patients with decompensated heart failure: a multimarker paradigm. <i>Journal of Cardiovascular Translational Research</i> , 2009 , 2, 526-35	3.3	15
749	Biomarkers in heart failure--better than history or echocardiography?. 2009 , 34, 581-8		8
748	Marqueurs biochimiques de l'insuffisance cardiaque (IC). 2009 , 2009, 59-64		
747	B type natriuretic peptide--a diagnostic breakthrough in peri-operative cardiac risk assessment?. 2009 , 64, 165-78		28
746	Emergency thoracic ultrasound in the differentiation of the etiology of shortness of breath (ETUDES): sonographic B-lines and N-terminal pro-brain-type natriuretic peptide in diagnosing congestive heart failure. 2009 , 16, 201-10		198
745	Cardiac biomarkers for risk stratification in non-massive pulmonary embolism: a multicenter prospective study. 2009 , 7, 391-8		86
744	Utility of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) to distinguish between congestive heart failure and non-cardiac causes of acute dyspnea in cats. 2009 , 11 Suppl 1, S51-61		75
743	Plasma concentrations of natriuretic peptides in normal cats and normotensive and hypertensive cats with chronic kidney disease. 2009 , 11 Suppl 1, S71-9		33
742	Assessment of the diagnostic accuracy of circulating natriuretic peptide concentrations to distinguish between cats with cardiac and non-cardiac causes of respiratory distress. 2009 , 11 Suppl 1, S41-50		43
741	Effect of renal function loss on NT-proBNP level variations. 2009 , 42, 1091-8		13
740	S3 detection as a diagnostic and prognostic aid in emergency department patients with acute dyspnea. 2009 , 53, 748-57		55
739	Prevalentie en onjuiste diagnoses van chronisch hartfalen bij verpleeghuisbewoners: de rol van B-type natriuretische peptiden. 2009 , 34, 4-9		
738	Natriuretic peptide determinations in critical care medicine: part of routine clinical practice or research test only?. 2009 , 13, 105		2
737	Midregional pro-adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study. 2009 , 13, R122		41

736	Introduction of an NT-proBNP assay to an acute admission unit--a 2-year audit. 2009 , 20, 58-62		6
735	The additive value of N-terminal pro-B-type natriuretic peptide testing at the emergency department in patients with acute dyspnoea. 2009 , 20, 301-6		5
734	B-type natriuretic peptide and impedance cardiography at the time of routine echocardiography predict subsequent heart failure events. 2009 , 15, 41-7		11
733	Reduction in BNP levels with treatment of decompensated heart failure and future clinical events. 2009 , 15, 293-9		44
732	Role for precursor Pro-B type natriuretic peptide in assessing response to therapy and prognosis in patients with decompensated heart failure treated with nesiritide. 2009 , 406, 119-23		11
731	Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema. <i>International Journal of Cardiology</i> , 2009 , 135, 165-74	3.2	20
730	Effect of bradyarrhythmia on the plasma levels of N-terminal pro-brain natriuretic peptide. <i>International Journal of Cardiology</i> , 2009 , 136, 105-7	3.2	1
729	[Diagnosing the cause of acute dyspnea in elderly patients: role of biomarkers in emergencies]. 2009 , 38, 1506-15		4
728	Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study. 2009 , 157, 746-53.e2		73
727	Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. 2009 , 158, 422-30		261
726	B-type natriuretic peptides for the evaluation of exercise intolerance. 2009 , 122, 265-72		11
725	The role of b-type natriuretic peptide in heart failure management. 2009 , 22, 117-23		12
724	Acute heart failure: How to evaluate left ventricular filling pressure in practice?. 2009 , 102, 319-26		1
723	Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. 2009 , 53, 884-90		127
722	Heart failure with normal left ventricular ejection fraction. 2009 , 53, 905-18		197
721	End points for clinical trials in acute heart failure syndromes. 2009 , 53, 2248-58		84
720	Improving the diagnosis of acute heart failure using a validated prediction model. 2009 , 54, 1515-21		47
719	Natriuretic peptide-guided therapy for heart failure: ready for "battle" or too "scarred" by the challenges of trial design?. 2009 , 55, 61-4		12

718	[Urinary levels of B-type natriuretic peptide (BNP) and ventricular systolic dysfunction in heart failure patients]. 2009 , 209, 168-75	1
717	Assessment of serum N-terminal pro-B-type natriuretic peptide concentration for differentiation of congestive heart failure from primary respiratory tract disease as the cause of respiratory signs in dogs. 2009 , 235, 1319-25	46
716	BNP-guided therapy for heart failure. 2009 , 301, 432-4	18
715	Can new pulmonary gas exchange parameters contribute to evaluation of pulmonary congestion in left-sided heart failure?. 2009 , 25, 149-55	4
714	Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials. 2009 , 25, 85-105	64
713	Point-of-care testing for cardiac markers in acute coronary syndromes and heart failure. 2009 , 29, 561-71	12
712	Natriuretic peptides in the diagnosis and management of acute heart failure. 2009 , 5, 489-500	8
711	ST2 and adrenomedullin in heart failure. 2009 , 5, 515-27	6
710	Diagnosis of heart failure. 2009 , 5, 25-35, vi	19
709	Emergency department presentation of heart transplant recipients with acute heart failure. 2009 , 5, 129-43, viii	4
708	Early assessment of outcome in cardiogenic shock: relevance of plasma N-terminal pro-B-type natriuretic peptide and interleukin-6 levels. 2009 , 37, 1837-44	36
707	Natriuretic peptide testing for heart failure therapy guidance in the inpatient and outpatient setting. 2009 , 16, 171-7	9
706	[NT-proBNP in practice: from chemistry to medicine]. 2009 , 67, 255-71	8
705	Natriuretic peptide-guided management of acutely destabilized heart failure: rationale and treatment algorithm. 2009 , 8, 146-50	19
704	Natriuretic peptide guided heart failure management. 2009 , 4, 87-94	10
703	B-Type Natriuretic Peptides for the Evaluation of Exercise Intolerance. 2010 , 2010, 234-236	1
702	Place des marqueurs biologiques en cardiologie. 2010 , 5, 1-10	
701	Relation of Vigorous Exercise to Risk of Atrial Fibrillation. 2010 , 2010, 236-238	

700	Prediction of cardiogenic shock using plasma B-type natriuretic peptide and the N-terminal fragment of its pro-hormone [corrected] concentrations in ST elevation myocardial infarction: an analysis from the ASSENT-4 Percutaneous Coronary Intervention Trial. 2010 , 38, 1793-801	13
699	Meta-analysis: effect of B-type natriuretic peptide testing on clinical outcomes in patients with acute dyspnea in the emergency setting. 2010 , 153, 728-35	44
698	Preoperative Evaluation. 2010 , 1001-1066	20
697	Natriuretic peptides in heart failure. 2010 , 7, 355-365	
696	Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure. 2010 , 267, 119-29	48
695	[Importance of surfactant proteins B and D for the differential diagnosis of acute dyspnea]. 2010 , 105, 611-8	1
694	Effects of sample handling on serum N-terminal proB-type natriuretic peptide concentration in normal dogs and dogs with heart disease. 2010 , 12, 41-8	11
693	Biomarkers in the management of heart failure. 2010 , 12, 519-31	17
692	Benefits of biomarkers in heart failure. 2010 , 5, 21-26	
691	Use of multiple biomarkers in heart failure. 2010 , 12, 230-6	11
690	Biomarkers in heart failure: a clinical review. 2010 , 15, 251-73	19
689	Biomarker guided therapy for heart failure: focus on natriuretic peptides. 2010 , 15, 351-70	13
688	Utility of natriuretic peptide testing in the evaluation and management of acute decompensated heart failure. 2010 , 15, 275-91	5
687	Clinical applications of N-terminal pro B-type natriuretic peptide in heart failure and other cardiovascular diseases. 2010 , 15, 293-304	15
686	Efficacy and safety of nicorandil therapy in patients with acute heart failure. 2010 , 56, 339-47	9
685	High N-terminal pro-B-type natriuretic peptide: a biomarker of lung cancer?. 2010 , 11, 341-5	12
684	Biomarkers in Heart Failure. 2010 , 27-43	
683	High circulating levels of N-terminal pro-brain natriuretic peptide and interleukin 6 in patients with mixed cryoglobulinemia. 2010 , 82, 297-303	9

682	Post-discharge changes in NT-proBNP and quality of life after acute dyspnea hospitalization as predictors of one-year outcomes. 2010 , 43, 1405-10		12
681	Diagnostic accuracy of emergency Doppler echocardiography for identification of acute left ventricular heart failure in patients with acute dyspnea: comparison with Boston criteria and N-terminal prohormone brain natriuretic peptide. 2010 , 17, 18-26		41
680	High levels of circulating N-terminal pro-brain natriuretic peptide in patients with hepatitis C. 2010 , 17, 851-3		14
679	Heart failure and COPD: partners in crime?. 2010 , 15, 895-901		21
678	Perioperative brain natriuretic peptide in off-pump coronary artery bypass. 2010 , 65, 297-301		2
677	[Study on interpretation of quantitative results of prostate-specific antigen using information theory]. 2010 , 30, 357-63		
676	Molecular forms of natriuretic peptides in heart failure and their implications. 2010 , 96, 419-24		35
675	Determining the aetiology of pulmonary oedema by the oedema fluid-to-plasma protein ratio. 2010 , 35, 331-7		50
674	The effect of renal dysfunction on BNP, NT-proBNP, and their ratio. 2010 , 133, 14-23		80
673	Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients. 2010 , 56, 1814-21		40
672	B-type natriuretic peptides and the promise of improved cardiovascular risk prediction. 2010 , 56, 883-5		1
671	Hyponatremia, natriuretic peptides, and outcomes in acutely decompensated heart failure: results from the International Collaborative of NT-proBNP Study. <i>Circulation: Heart Failure</i> , 2010 , 3, 354-61	7.6	46
670	Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. 2010 , 122, 1975-96		206
669	Use of myeloperoxidase for risk stratification in acute heart failure. 2010 , 56, 944-51		79
668	Differential prognostic utility of NTproBNP and Cystatin C in patients with acute exacerbation of chronic pulmonary disease. 2010 , 1, 44		1
667	Improvement of the cardiac marker N-terminal-pro brain natriuretic peptide through adjustment for renal function: a stratified multicenter trial. 2010 , 48, 121-8		10
666	Heart Failure in Clinical Practice. 2010 ,		4
665	Dynamic changes in N-terminal pro-brain natriuretic peptide in acute coronary syndromes treated with percutaneous coronary intervention: a marker of ischemic burden, reperfusion and outcome. 2010 , 48, 875-81		11

664	Effect of sialylated O-glycans in pro-brain natriuretic peptide stability. 2010 , 56, 959-66		34
663	Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. <i>European Journal of Heart Failure</i> , 2010 , 12, 826-32	12.3	243
662	N-terminal pro-brain natriuretic peptide and tumor necrosis factor-alpha both are increased in patients with Hepatitis C. 2010 , 30, 359-63		11
661	Decompensated chronic heart failure: increased liver stiffness measured by means of transient elastography. 2010 , 257, 872-8		128
660	Red blood cell distribution width and 1-year mortality in acute heart failure. <i>European Journal of Heart Failure</i> , 2010 , 12, 129-36	12.3	170
659	Increase in N-terminal fragment of the prohormone brain-type natriuretic peptide as a measure for predicting outcome after urgent heart transplantation. 2010 , 37, 864-9		2
658	Use of biomarkers in evaluation of patients with heart failure. 2010 , 164, 88-117		2
657	Biomarkers of cardiac and kidney dysfunction in cardiorenal syndromes. 2010 , 165, 83-92		9
656	Impact of increased body mass index on accuracy of B-type natriuretic peptide (BNP) and N-terminal proBNP for diagnosis of decompensated heart failure and prediction of all-cause mortality. 2010 , 56, 633-41		31
655	N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. 2010 , 31, 120-7		92
654	Natriuretic peptide-guided management of patients with heart failure: a decade of progress but still a controversy. 2010 , 6, 743-7		3
653	New York Heart Association class versus amino-terminal pro-B type natriuretic peptide for acute heart failure prognosis. 2010 , 15, 307-14		15
652	Nouveaux biomarqueurs de la pathologie cardiovasculaire et infectieuse en médecine d'urgence. 2010 , 19, 648-654		1
651	Diagnostic d'une insuffisance cardiaque aiguë aux urgences: intérêt d'une approche multimarqueur. 2010 , 19, 103-110		1
650	National Heart, Lung, and Blood Institute working group on emergency department management of acute heart failure: research challenges and opportunities. 2010 , 56, 343-51		64
649	Peptidi natriuretici e broncopneumopatia cronica ostruttiva nel Dipartimento di Emergenza. 2010 , 4, 247-253		1
648	Relative value of amino-terminal pro-B-type natriuretic peptide testing and radiographic standards for the diagnostic evaluation of heart failure in acutely dyspneic subjects. 2010 , 15, 175-82		7
647	In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: the Italian RED Study. 2010 , 14, R116		50

646	Copeptin and risk stratification in patients with acute dyspnea. 2010 , 14, R213		40
645	Impact of history of heart failure on diagnostic and prognostic value of BNP: results from the B-type Natriuretic Peptide for Acute Shortness of Breath Evaluation (BASEL) study. <i>International Journal of Cardiology</i> , 2010 , 142, 265-72	3.2	21
644	N-terminal pro B-type natriuretic peptide predicts mortality in patients with left ventricular hypertrophy. <i>International Journal of Cardiology</i> , 2010 , 143, 349-52	3.2	9
643	[Biomarkers for detection and prediction in acute coronary syndrome]. 2010 , 134, 499-504		1
642	Use of hand carried ultrasound, B-type natriuretic peptide, and clinical assessment in identifying abnormal left ventricular filling pressures in patients referred for right heart catheterization. 2010 , 16, 69-75		35
641	Section 4: Evaluation of Patients for Ventricular Dysfunction and Heart Failure. 2010 , 16, e44-e56		3
640	Section 12: Evaluation and Management of Patients with Acute Decompensated Heart Failure. 2010 , 16, e134-e156		4
639	Natriuretic peptides: the feline experience. 2010 , 40, 559-70		8
638	The use of NT-proBNP assay in the management of canine patients with heart disease. 2010 , 40, 545-58		19
637	Clinical utility of NT-proBNP levels in late heart transplantation patients. 2010 , 411, 161-6		6
636	Sequencing and cardiac expression of natriuretic peptide receptors A and C in normal and heart failure pigs. 2010 , 162, 12-7		12
635	Serial measurements of serum NT-proBNP as markers of left ventricular systolic function and remodeling in children with heart failure. 2010 , 160, 776-83		41
634	ST2: a novel biomarker for heart failure. 2010 , 10, 459-64		55
633	Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. 2010 , 31, 703-11		581
632	Biomarkers of Cardiac Injury. 2010 , 119-155		1
631	Diagnosing destabilized heart failure in the emergency setting: current and future biomarker tests. 2011 , 15, 327-40		
630	Usefulness of N-terminal pro-brain natriuretic peptide and C-reactive protein to predict ICU mortality in unselected medical ICU patients: a prospective, observational study. 2011 , 15, R42		18
629	Natriuretic peptide testing in heart failure. 2011 , 123, 2015-9		174

628	Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. <i>European Journal of Heart Failure</i> , 2011 , 13, 518-27	12.3	84
627	Critical care in the emergency department: acute respiratory failure. 2011 , 28, 94-7		8
626	Cardiac biomarkers in the critically ill. 2011 , 27, 327-43		
625	Novel biomarkers in human terminal heart failure and under mechanical circulatory support. 2011 , 16 Suppl 1, S31-41		20
624	NT-proBNP, NT-proANP and cTnI concentrations in dogs with pre-capillary pulmonary hypertension. 2011 , 13, 171-82		32
623	Comprehensive Cardiovascular Medicine in the Primary Care Setting. 2011 ,		
622	The Use of Biomarkers in the Evaluation of Heart Failure. 2011 , 545-559		1
621	Natriuretic peptide testing in EDs for managing acute dyspnea: a meta-analysis. 2011 , 29, 757-67		30
620	Biochemical markers in acute coronary syndrome. 2011 , 412, 1279-96		34
619	Acute heart failure: lessons learned so far. 2011 , 27, 284-95		9
618	Brain natriuretic peptide measurement in pulmonary medicine. <i>Respiratory Medicine</i> , 2011 , 105, 1770-5	4.6	6
617	Combination of lung ultrasound (a comet-tail sign) and N-terminal pro-brain natriuretic peptide in differentiating acute heart failure from chronic obstructive pulmonary disease and asthma as cause of acute dyspnea in prehospital emergency setting. 2011 , 15, R114		93
616	Additive value of torsion to global longitudinal left ventricular strain in patients with reduced ejection fraction. 2011 , 66, 565-72		3
615	Clinical Use of Natriuretic Peptides. 2011 , 20, 312-315		0
614	Utilization of B-type natriuretic peptide and NT-proBNP in the diagnosis of pleural effusions due to heart failure. 2011 , 17, 215-9		31
613	Serum N-terminal pro-B-type natriuretic peptide levels at the time of hospital admission predict of microvascular obstructions after primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. 2011 , 24, 34-41		7
612	N-terminal probrain natriuretic peptide as a biomarker of cardioembolic stroke. 2011 , 6, 398-403		24
611	Biomarkers in advanced heart failure: diagnostic and therapeutic insights. 2011 , 17, 169-74		9

610	Clinical significance of the measurements of plasma N-terminal pro-B-type natriuretic peptide levels in patients with coronary artery disease who have undergone elective drug-eluting stent implantation. 2011 , 57, 303-10		6
609	Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. <i>American Journal of Cardiology</i> , 2011 , 107, 259-67	3	161
608	Relation of visceral adiposity to circulating natriuretic peptides in ambulatory individuals. <i>American Journal of Cardiology</i> , 2011 , 108, 979-84	3	41
607	Laboratory parameters of cardiac and kidney dysfunction in cardio-renal syndromes. 2011 , 16, 545-51		22
606	Kardiale Biomarker in der Notfallmedizin. 2011 , 14, 229-242		0
605	Use of novel and conventional biomarkers for management of patients with heart failure. 2011 , 13, 475-88		7
604	Peptides natriurétiques, biomarqueurs de l'insuffisance cardiaque aux urgences. 2011 , 1, 200-205		
603	Updating the role of natriuretic peptide levels in cardiovascular disease. 2011 , 123, 102-13		19
602	Biomarkers in kidney and heart disease. 2011 , 26, 62-74		38
601	Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. 2011 , 96, 3242-9		114
600	Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL Evaluation Along with B-type Natriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. <i>European Journal of Heart Failure</i> , 2011 , 13, 846-51	12.3	188
599	Directions from Hecate: towards a multi-marker approach for heart failure assessment. <i>European Journal of Heart Failure</i> , 2011 , 13, 691-3	12.3	3
598	Increased serum N-terminal pro-B-type natriuretic peptide levels in patients with medial arterial calcification and poorly compressible leg arteries. 2011 , 31, 197-202		19
597	Can Brain Natriuretic Peptide (BNP) be a Predictor for Pulmonary Arterial Hypertension?. 2011 , 12, 134-138		
596	[Relationship between coronary collateral circulation and plasma levels of N-terminal pro-B-type natriuretic peptide]. 2011 , 11, 29-33		4
595	Impact of growth hormone (GH) treatment on circulating Nt-proBNP concentrations and on cardiac function in adult GH-deficient patients. 2012 , 72, 387-94		7
594	Congestive Heart Failure. 2012 , 405-412		
593	Pre-admission NT-proBNP improves diagnostic yield and risk stratification - the NT-proBNP for Evaluation of dyspnoeic patients in the Emergency Room and hospital (BNP4EVER) study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2012 , 1, 99-108	4.3	11

592	Plasma adrenomedullin and subclinical cardiorenal syndrome in patients with type 2 diabetes mellitus. 2012 , 40, 1552-9	4
591	Equal performance of novel N-terminal proBNP (Cardiac proBNP [®]) and established BNP (Triage BNP [®]) point-of-care tests. 2012 , 6, 789-96	9
590	Galectin 3 complements BNP in risk stratification in acute heart failure. 2012 , 17, 706-13	39
589	N-terminal pro brain natriuretic peptide in the management of patients in the medical emergency department (PROMPT): correlation with disease severity, utilization of hospital resources, and prognosis in a large, prospective, randomized multicentre trial. <i>European Journal of Heart Failure</i> , 2012 , 14, 253-61	12.3 21
588	Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure. 2012 , 33, 2317-24	55
587	Increased cardiac troponin I as measured by a high-sensitivity assay is associated with high odds of cardiovascular death: the Minnesota Heart Survey. 2012 , 58, 930-5	49
586	Successful pulmonary endarterectomy in a patient with klinefelter syndrome. 2012 , 2012, 104195	1
585	Comparison of the diagnostic performance of three natriuretic peptides in hemodialysis patients: which is the appropriate biomarker?. 2012 , 36, 172-81	11
584	Fluid Overload in Heart Failure and Cardiorenal Syndrome: The B B Approach. 2012 , 643-652	
583	Relative Change in NT-proBNP Level: An Important Risk Predictor of Cardiovascular Congestion in Haemodialysis Patients. 2012 , 2, 311-8	7
582	Biomarkers in patients with acute dyspnoea: what for?. 2012 , 33, 2124-6	4
581	Amino-terminal pro-brain natriuretic peptide as a predictor of outcome in patients admitted to intensive care. A prospective observational study. 2012 , 29, 275-9	8
580	Hepatitis C is Associated with High Levels of Circulating N-Terminal Pro-Brain Natriuretic Peptide and Interleukin-6. 2012 , 10, 133-138	3
579	The role of natriuretic peptides: from the emergency department throughout hospitalization. 2012 , 18 Suppl 1, S5-8	6
578	Circulating natriuretic peptide concentrations in hyperthyroid cats. 2012 , 53, 673-8	15
577	Measurement of NT-proBNP with LOCI technology in heart failure patients. 2012 , 45, 171-4	3
576	Head-to-head comparison of the prohormone proBNP1-108 with BNP and Nt-proBNP in patients admitted to emergency department. 2012 , 45, 249-52	5
575	Diagnostic power of the mid-regional pro-atrial natriuretic peptide for heart failure patients with dyspnea: a meta-analysis. 2012 , 45, 1634-9	15

574	Le NT-proBNP dans l'insuffisance cardiaque des sujets noirs africains : quels seuils faut-il retenir en ambulatoire ?. 2012 , 27, 249-253	
573	Biomarker-guided therapy for heart failure. 2012 , 64, 178-81	
572	Correlation between NT proBNP and left ventricular ejection fraction in elderly patients presenting to emergency department with dyspnoea. 2012 , 64, 302-4	5
571	Diagnosis and management of fluid overload in heart failure and cardio-renal syndrome: the "5B" approach. 2012 , 32, 129-41	59
570	Evaluaci3n econ3mica de la determinaci3n del peptido natriur3tico cerebral n-terminal (NT-proBNP) en pacientes con disnea en los servicios de urgencias espa0oles. 2012 , 5, 155-164	
569	Effective strategies to improve the management of heart failure. 2012 , 39, 393-413	5
568	Extracorporeal ultrafiltration in heart failure and cardio-renal syndromes. 2012 , 32, 100-11	5
567	Brain Natriuretic Peptide. 2012 , 1, e289-e299	
566	Diagnostic value of NT-proBNP in cardiogenic and non cardiogenic pleural effusions. 2012 , 61, 109-114	
565	Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. 2012 , 33, 2001-6	176
564	The effect of diabetes on the diagnostic and prognostic performance of mid-region pro-atrial natriuretic peptide and mid-region pro-adrenomedullin in patients with acute dyspnea. 2012 , 17, 490-7	4
563	The role of biomarkers and B-type natriuretic peptide in diagnosis and perioperative risk prediction. 2012 , 18, 303-308	1
562	Cardio-renal syndrome type 3: epidemiology, pathophysiology, and treatment. 2012 , 32, 31-9	44
561	Biomarkers in acute myocardial injury. 2012 , 159, 252-64	78
560	Clinical utility of natriuretic peptides in dialysis patients. 2012 , 25, 326-33	21
559	The diagnostic utility of cardiac biomarkers in dialysis patients. 2012 , 25, 388-96	18
558	The novel marker LTBP2 predicts all-cause and pulmonary death in patients with acute dyspnoea. 2012 , 123, 557-66	15
557	A pilot study to examine relationships among external counterpulsation, cardiac output, functional capacity, and quality of life. 2012 , 25, 117-22	

556	Brain natriuretic peptide in the evaluation of emergency department dyspnea: is there a role?. 2012 , 42, 197-205	23
555	Corin in clinical laboratory diagnostics. 2012 , 413, 378-83	46
554	Prognostic value of combining high sensitive troponin T and N-terminal pro B-type natriuretic peptide in chest pain patients with no persistent ST-elevation. 2012 , 413, 933-7	13
553	Red blood cell distribution width predicts early mortality in patients with acute dyspnea. 2012 , 413, 992-7	29
552	Prognostic significance of applying the European Society of Cardiology consensus algorithm for heart failure with preserved systolic function diagnosis. 2012 , 35, 770-6	11
551	The REFER (REFer for Echocardiogram) protocol: a prospective validation of a clinical decision rule, NT-proBNP, or their combination, in the diagnosis of heart failure in primary care. Rationale and design. 2012 , 12, 97	13
550	Helical computerized tomography and NT-proBNP for screening of right ventricular overload on admission and at long term follow-up of acute pulmonary embolism. 2012 , 20, 33	4
549	Le NT-proBNP. 2012 , 85-90	
548	Apport du dosage du BNP dans la prise en charge des dyspnées aiguës. 2012 , 197-200	
547	Intérêt et limites des biomarqueurs chez les patients avec décompensation de bronchopneumopathie chronique obstructive. 2012 , 217-229	
546	Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. 2012 , 164, 793-799.e1	45
545	Breathing not properly 10 years later: what we have learned and what we still need to learn. 2012 , 60, 277-82	35
544	Multimarker strategy for short-term risk assessment in patients with dyspnea in the emergency department: the MARKED (Multi mARKer Emergency Dyspnea)-risk score. 2012 , 60, 1668-77	29
543	Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study. 2012 , 18, 626-34	57
542	Copeptin in the assessment of acute lung injury and cardiogenic pulmonary edema. <i>Respiratory Medicine</i> , 2012 , 106, 1268-77	4.6 18
541	Role of biomarkers in the diagnosis and management of cardio-renal syndromes. 2012 , 32, 79-92	31
540	Perioperative serum brain natriuretic peptide and cardiac troponin in elective intracranial surgery. 2012 , 17, 395-400	8
539	Integrating Optimal Use of Echocardiography and Biomarkers in Heart Disease. 2012 , 5, 444-451	

538	Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. 2012 , 33, 2197-205	106
537	Manual of Outpatient Cardiology. 2012 ,	
536	Les biomarqueurs en médecine d'urgence. 2012 ,	
535	Narrative review: the management of acute decompensated heart failure. 2012 , 27, 343-53	7
534	The appropriate use of biomarkers in heart failure. 2012 , 96, 901-13	3
533	Diagnostic value of N-terminal ProB-Type Natriuretic Peptide in Emergency Department: Analysis by subgroups. 2012 , 8, 34	
532	Bio-Markers and Cardiorenal Disease: Prognostic and Clinical Relevance. 2012 , 24, 69-76	
531	Towards clinical applications of selected reaction monitoring for plasma protein biomarker studies. 2012 , 6, 42-59	13
530	Evaluation of cardiovascular risk in patients with rheumatoid arthritis: do cardiovascular biomarkers offer added predictive ability over established clinical risk scores?. 2012 , 64, 817-25	33
529	A rational approach to assess volume status in patients with decompensated heart failure. 2012 , 9, 139-47	1
528	A comparison of criterion standard methods to diagnose acute heart failure. 2012 , 18, 262-71	11
527	Biochemical markers in heart failure. 2012 , 59, 1-7	40
526	Increased serum N-terminal pro-B-type natriuretic peptide and left ventricle diastolic dysfunction in patients with hepatitis C virus infection. 2012 , 19, 327-31	13
525	N-terminal proB-type natriuretic peptide levels aid the diagnosis of left ventricular dysfunction in patients with severe acute exacerbations of chronic obstructive pulmonary disease and renal dysfunction. 2012 , 17, 660-6	13
524	Cardiac biomarkers in the intensive care unit. 2012 , 2, 8	11
523	Prognostic markers for acute heart failure. 2013 , 7, 379-92	9
522	The role of the emergency department in the patient with acute heart failure. 2013 , 15, 365	7
521	Evaluation of heart failure biomarker tests: a survey of statistical considerations. <i>Journal of Cardiovascular Translational Research</i> , 2013 , 6, 449-57	33 9

520	New and emerging biomarkers in left ventricular systolic dysfunction--insight into dilated cardiomyopathy. <i>Journal of Cardiovascular Translational Research</i> , 2013 , 6, 516-27	3.3	24
519	Novel biomarkers for heart failure. 2013 , 11, 1155-69		18
518	Analytical and assay issues for use of cardiac troponin testing for risk stratification in primary care. 2013 , 46, 969-978		40
517	Primary results of the HABIT Trial (heart failure assessment with BNP in the home). 2013 , 61, 1726-35		72
516	2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. 2013 , 128, e240-327		1927
515	Determination of a predictive cutoff value of NT-proBNP testing for long-term survival in ED patients with acute heart failure. 2013 , 31, 1634-7		8
514	Anwendung und Nutzen kardialer Biomarker in der Praxis. 2013 , 7, 377-386		
513	Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. <i>Journal of Cardiovascular Translational Research</i> , 2013 , 6, 1011-20	3.3	109
512	Treatment strategies for the prevention of heart failure. 2013 , 10, 331-40		7
511	Incorporating common biomarkers into the clinical management of heart failure. 2013 , 10, 450-7		5
510	C-type natriuretic peptide: a new cardiac mediator. 2013 , 40, 93-8		34
509	Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort. 2013 , 61, 820-9		85
508	Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment. 2013 , 88, 234-43		48
507	Value of proBNP1-108 testing for the risk stratification of patients with systolic heart failure. 2013 , 50, 125-8		3
506	[Prognostic role of NT-proBNP in emergency department in the elderly with acute heart failure]. 2013 , 48, 155-60		5
505	Clinical usefulness of an assay for measurement of circulating N-terminal pro-B-type natriuretic peptide concentration in dogs and cats with heart disease. 2013 , 243, 71-82		36
504	Clinical utility of biomarkers in chronic kidney disease and chronic heart failure. 2013 , 39, 128-39		1
503	Diagnosing heart failure among acutely dyspneic patients with cardiac, inferior vena cava, and lung ultrasonography. 2013 , 31, 1208-14		101

502	Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure. <i>International Journal of Cardiology</i> , 2013 , 168, 3404-11	3.2	54
501	Measurement of natriuretic peptides at the point of care in the emergency and ambulatory setting: current status and future perspectives. 2013 , 166, 614-621.e1		8
500	Predictive cutoff point of admission N-terminal pro-B-type natriuretic peptide testing in the ED for prognosis of patients with acute heart failure. 2013 , 31, 1191-5		12
499	Servicios de urgencia m�dica y pptidos natriur�ticos: �hay que pedirlos siempre?. 2013 , 6, 186-187		
498	Initial management of patients with acute heart failure. 2013 , 9, 291-301, vi		9
497	Diagnostic and prognostic property of NT-proBNP in patients with renal dysfunction. 2013 , 61, 446-7		5
496	Association between chronic hepatitis C virus infection and high levels of circulating N-terminal pro-brain natriuretic peptide. 2013 , 43, 200-5		3
495	Prospective evaluation of B-type natriuretic peptide concentrations and the risk of type 2 diabetes in women. 2013 , 59, 557-65		22
494	Biomarkers and diagnostics in heart failure. 2013 , 1832, 2442-50		212
493	Heart failure. 2013 , 1, 1-20		481
492	2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 , 62, e147-239		4318
491	Investigating suspected heart failure. 2013 , 346, f2442		2
490	The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs. 2013 , 42, 196-206		12
489	Treatment of acute heart failure in the emergency department. 2013 , 11, 1195-209		3
488	Role of B-type natriuretic peptide as a marker of mortality in acute kidney injury patients treated with continuous renal replacement therapy. 2013 , 35, 1216-22		3
487	Natriuretic peptides, novel biomarkers, and the prediction of future events. 2013 , 34, 419-21		2
486	ProANP plasma measurement predicts all-cause mortality in acutely hospitalised patients: a cohort study. 2013 , 3, e003288		9
485	Mid-regional pro-adrenomedullin improves disposition strategies for patients with acute dyspnoea: results from the BACH trial. 2013 , 30, 633-7		11

484	Using biomarkers to "guide" heart failure management: current perspectives and future directions. 2013 , 21, 127-34	7
483	Prognostic and diagnostic value of plasma soluble suppression of tumorigenicity-2 concentrations in acute respiratory distress syndrome. 2013 , 41, 2521-31	38
482	Chief complaints in medical emergencies: do they relate to underlying disease and outcome? The Charit'Emergency Medicine Study (CHARITEM). 2013 , 20, 103-8	138
481	Natriuretic peptides: molecular biology, pathophysiology and clinical implications for the cardiologist. 2013 , 9, 519-34	9
480	Analytical and clinical evaluation of biomarkers assays: when are biomarkers ready for prime time?. 2013 , 10, 666-76	28
479	Biological variation and prognosis usefulness of new biomarkers in liver transplantation. 2013 , 51, 1241-9	5
478	[Biomarkers of cardiorenal syndrome]. 2013 , 71, 409-18	2
477	Characterization and prediction of natriuretic peptide "nonresponse" during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study. 2013 , 13, 135-42	30
476	Time course of NT-proBNP levels after acute ischemic stroke. 2013 , 128, 235-40	11
475	Natriuretic peptides as biomarkers in heart failure. 2013 , 61, 950-5	24
474	Inflammatory markers in heart failure: hype or hope?. 2013 , 14, 342-50	4
473	Natriuretic peptide type B in burn intensive care. 2013 , 74, 855-61	8
472	Old and newer biomarkers in heart failure: from pathophysiology to clinical significance. 2013 , 14, 690-7	8
471	Association of serum carotenoid levels with N-terminal pro-brain-type natriuretic peptide: a cross-sectional study in Japan. 2013 , 23, 163-8	8
470	Agreement of BNP and NT-proBNP and the influence of clinical and laboratory variables. 2013 , 11, 273-7	11
469	[Clinical usefulness of biomarkers in cardiac failure]. 2013 , 141, 1560-9	1
468	The ability of NT-proBNP to detect chronic heart failure and predict all-cause mortality is higher in elderly Chinese coronary artery disease patients with chronic kidney disease. 2013 , 8, 409-17	9
467	Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP). 2013 , 24, 286-9	39

- 466 N-Terminal Pro-Brain Natriuretic Peptide: Prognostic Potential in End Stage Liver Cirrhosis in a Cohort Free of Heart Failure; an Egyptian Insight. **2013**, 2,
- 465 Galectin-3: clinical utility and prognostic value in patients with heart failure. **2013**, 13 8
- 464 [Interest of NT-proBNP in chronic heart failure follow-up]. **2013**, 71, 39-45
- 463 Decompensated heart failure. **2013**, 11, 383-91 13
- 462 A novel cardiac bio-marker: ST2: a review. **2013**, 18, 15314-28 85
- 461 B-type natriuretic peptide and COPD in the Emergency Department. **2013**, 247-253
- 460 Changes in plasma levels of B-type natriuretic peptide with acute exacerbations of chronic obstructive pulmonary disease. **2014**, 9, 155-62 20
- 459 Cautious application of pleural N-terminal pro-B-type natriuretic peptide in diagnosis of congestive heart failure pleural effusions among critically ill patients. **2014**, 9, e115301 6
- 458 Cardiac Biomarkers. **2014**, 3
- 457 Clinical pathology of disorders of the mediastinum. 276-284
- 456 Evolution of biomarker guided therapy for heart failure: current concepts and trial evidence. **2015**, 11, 80-9 11
- 455 Biomarkers in hypertension and their relationship with myocardial target-organ damage. **2014**, 16, 502 1
- 454 Biomarkers of acute rejection following cardiac transplantation. **2014**, 8, 815-32 10
- 453 The relationship between BNP, NTproBNP and echocardiographic measurements of systemic blood flow in very preterm infants. **2014**, 34, 296-300 6
- 452 Prognostic significance of a multimarker strategy of biomarkers in acute heart failure. **2014**, 8, MC01-6 5
- 451 Design, methods, baseline characteristics and interim results of the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. **2014**, 5, 11-18 16
- 450 [Essential cardiac biomarkers in myocardial infarction and heart failure]. **2014**, 39, 727-39; quiz 740-1 1
- 449 The effects of running a 308 km ultra-marathon on cardiac markers. **2014**, 14 Suppl 1, S92-7 26

448	Dynamic use of B-type natriuretic peptide-guided acute coronary syndrome therapy. <i>American Journal of the Medical Sciences</i> , 2014 , 348, 283-7	2.2	2
447	Emerging biomarkers for acute heart conditions. 2014 , 29, 312-8		13
446	Comprehensive review of the prognostic value of galectin-3 in heart failure. 2014 , 22, 171-5		25
445	Predicting risk of coronary events and all-cause mortality: role of B-type natriuretic peptide above traditional risk factors and coronary artery calcium scoring in the general population: the Heinz Nixdorf Recall Study. 2014 , 21, 1171-9		16
444	Determinants of N-terminal pro-brain natriuretic peptide variation in hemodialysis patients and prediction of survival. 2014 , 37, 138-45		7
443	Utility of point-of-care testing of natriuretic peptides (brain natriuretic peptide and n-terminal pro-brain natriuretic peptide) in the emergency department. 2014 , 4, 209-15		11
442	Monitoring the response to treatment of acute heart failure patients by ultrasonographic inferior vena cava collapsibility index. 2014 , 32, 403-7		24
441	Connective tissue growth factor (CTGF/CCN2): diagnostic and prognostic value in acute heart failure. <i>Clinical Research in Cardiology</i> , 2014 , 103, 107-16	6.1	23
440	B-type natriuretic peptide: distribution in the general population and the association with major cardiovascular and coronary events--the Heinz Nixdorf Recall Study. <i>Clinical Research in Cardiology</i> , 2014 , 103, 125-32	6.1	22
439	Metabolic actions of natriuretic peptides and therapeutic potential in the metabolic syndrome. 2014 , 144, 12-27		89
438	Evaluation of patients with heart failure. 2014 , 32, 47-62, viii		5
437	Using galectin-3 to reduce heart failure rehospitalization. 2014 , 10, 221-7		4
436	Cardiovascular disease risk prediction in women: is there a role for novel biomarkers?. 2014 , 60, 88-97		17
435	B-type natriuretic peptides improve cardiovascular disease risk prediction in a cohort of women. 2014 , 64, 1789-97		20
434	Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. <i>International Journal of Cardiology</i> , 2014 , 176, 611-7	3.2	153
433	Use of BNP and NT-proBNP for the diagnosis of heart failure in the emergency department: a systematic review of the evidence. 2014 , 19, 421-38		69
432	The Indian Consensus Document on cardiac biomarker. 2014 , 66, 73-82		2
431	Cardiac biomarkers in heart failure. 2014 , 47, 327-37		39

430	Body mass index and mortality in acutely decompensated heart failure across the world: a global obesity paradox. 2014 , 63, 778-85		168
429	Review of the prognostic value of galectin-3 in heart failure focusing on clinical utility of repeated testing. 2014 , 18, 599-604		9
428	Clinical and echocardiographic characteristics of elderly hospitalized patients with high levels of NT-proBNP without clinical diagnosis of heart failure. 2014 , 26, 607-13		4
427	Reference interval evaluation of high-sensitivity troponin T and N-terminal B-type natriuretic peptide in Vietnam and the US: The North South East West Trial. 2014 , 60, 758-64		20
426	Usefulness of N-terminal pro-brain natriuretic peptide levels to predict success of weaning from intra-aortic balloon pumping. <i>American Journal of Cardiology</i> , 2014 , 114, 942-5	3	4
425	Heart failure biomarkers at point-of-care: current utilization and future potential. 2014 , 14, 185-97		13
424	Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. 2014 , 167, 853-60.e4		105
423	Natriuretic peptides in heart failure and acute coronary syndrome. 2014 , 34, 43-58, vi		28
422	Cardiorenal syndrome. 2014 , 3, 30-37		2
421	Charting a roadmap for heart failure biomarker studies. 2014 , 2, 477-88		54
420	Natriuretic peptides in heart failure with preserved ejection fraction. 2014 , 10, 453-70		24
419	Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin. 2014 , 19, 267-84		26
418	10. Natriuretic peptides. 2014 , 181-194		
417	The injured patient in the ICU. 261-276		
416	Heart failure. 303-318		
415	Clinical presentation and outcome by age categories in acute heart failure: results from an international observational cohort. <i>European Journal of Heart Failure</i> , 2015 , 17, 1114-23	12.3	39
414	Galectin-3 in heart failure pathology--"another brick in the wall"?. 2015 , 70, 323-31		19
413	How to Improve Time to Diagnosis in Acute Heart Failure - Clinical Signs and Chest X-ray. 2015 , 1, 69-74		7

412	Biomarkers in Acute Decompensated Heart Failure. 2015 , 7, CMT.S18476	
411	Combined biomarker analysis for risk of acute kidney injury in patients with ST-segment elevation myocardial infarction. 2015 , 10, e0125282	28
410	Plasma ProBNP Is Not a Specific Marker for Transient Myocardial Ischemia. 2015 , 7, 506-10	1
409	Novel Biomarkers in Heart Failure Beyond Natriuretic Peptides - The Case for Soluble ST2. 2015 , 10, 37-41	3
408	Perioperative myocardial injury in patients receiving cardiac output-guided haemodynamic therapy: a substudy of the OPTIMISE Trial. 2015 , 115, 227-33	23
407	Cystatin C-based CKD-EPI equations and N-terminal pro-B-type natriuretic peptide for predicting outcomes in acutely decompensated heart failure. 2015 , 38, 106-13	17
406	State of the art of immunoassay methods for B-type natriuretic peptides: An update. 2015 , 52, 56-69	26
405	Inflammatory cytokines as biomarkers in heart failure. 2015 , 443, 71-7	68
404	Gestión de las peticiones de NT-proBNP y procalcitonina mediante reglas computarizadas basadas en criterios clínicos. 2015 , 8, 39-45	
403	The utility of inferior vena cava diameter and the degree of inspiratory collapse in patients with systolic heart failure. 2015 , 33, 653-7	17
402	Clinical utility of B-type natriuretic peptide (NP) in pediatric cardiac surgery--a systematic review. 2015 , 25, 115-26	8
401	Diagnostic performance of cardiopulmonary ultrasound performed by the emergency physician in the management of acute dyspnea. 2015 , 33, 352-8	51
400	Soluble ST2 in Ventricular Dysfunction. 2015 , 69, 139-59	4
399	N-terminal pro-B-type natriuretic peptide is also related to increased mortality. 2015 , 33, 729-30	
398	Cardiovascular Biomarker Assessment Across Glycemic Status. 2015 , 245-268	0
397	Soluble CD146, a new endothelial biomarker of acutely decompensated heart failure. <i>International Journal of Cardiology</i> , 2015 , 199, 241-7	3,2 30
396	Influence of glycosylation on diagnostic and prognostic accuracy of N-terminal pro-B-type natriuretic peptide in acute dyspnea: data from the Akershus Cardiac Examination 2 Study. 2015 , 61, 1087-97	38
395	Galectin-3 as a new biomarker of diastolic dysfunction in hemodialysis patients. 2015 , 40, 788-94	7

394	B-type Natriuretic Peptide circulating forms: Analytical and bioactivity issues. 2015 , 448, 195-205		33
393	Clinical value of NT-proBNP assay in the emergency department for the diagnosis of heart failure (HF) in very elderly people. 2015 , 61, 296-300		4
392	Biomarkers in acute heart failure. 2015 , 68, 514-25		11
391	Biomarcadores en la insuficiencia cardiaca aguda. 2015 , 68, 514-525		24
390	The potential role of natriuretic peptide-guided management for patients hospitalized for heart failure. 2015 , 21, 233-9		13
389	The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. 2015 , 350, h910		196
388	Association between N-terminal pro-brain natriuretic peptide and quality of life in adult patients with congenital heart disease. 2015 , 25, 288-94		5
387	Biomarkers in electrophysiology: role in arrhythmias and resynchronization therapy. 2015 , 43, 31-44		6
386	Usefulness of inferior vena cava in management of heart failure. 2015 , 33, 728-9		1
385	Prognostic value of B-type natriuretic peptide with the sequential organ failure assessment score in septic shock. <i>American Journal of the Medical Sciences</i> , 2015 , 349, 287-91	2.2	5
384	Natriuretic Peptides and Biomarkers in the Diagnosis of Heart Failure. 2015 , 211-229		1
383	Insuficiencia cardiaca aguda. 2015 , 11, 5201-5208		
382	The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management. 2015 , 13, 1017-30		30
381	Circulatory response to volume expansion and transjugular intrahepatic portosystemic shunt in refractory ascites: Relationship with diastolic dysfunction. 2015 , 47, 1052-8		12
380	The Current and Potential Clinical Relevance of Heart Failure Biomarkers. 2015 , 12, 318-27		9
379	Candidate biomarkers in heart failure with reduced and preserved ejection fraction. 2015 , 20, 258-65		5
378	Usefulness of B-type Natriuretic Peptides to Predict Cardiovascular Events in Women (from the Women's Health Study). <i>American Journal of Cardiology</i> , 2015 , 116, 532-7	3	10
377	Prognostic markers of acute decompensated heart failure: the emerging roles of cardiac biomarkers and prognostic scores. 2015 , 108, 64-74		23

376	Noninvasive tests for the diagnostic evaluation of dyspnea among outpatients: the Multi-Ethnic Study of Atherosclerosis lung study. 2015 , 128, 171-180.e5	18
375	Increase of circulating stromal cell-derived factor-1 in heart failure patients. 2015 , 40 Suppl 1, 70-5	5
374	Which biomarkers do clinicians need for diagnosis and management of heart failure with reduced ejection fraction?. 2015 , 443, 9-16	17
373	Cardiac biomarkers and clinical scores for risk stratification in elderly patients with non-high-risk pulmonary embolism. 2015 , 277, 707-16	17
372	Multiple biomarker strategies for risk stratification in heart failure. 2015 , 443, 120-5	17
371	Cardiopulmonary laboratory biomarkers in the evaluation of acute dyspnea. 2016 , 8, 35-45	14
370	The effect of surgical and non-surgical weight loss on N-terminal pro-B-type natriuretic peptide and its relation to obstructive sleep apnea and pulmonary function. 2016 , 9, 440	12
369	Comparison of Cardiac and Non-Cardiac Biomarkers for Risk Stratification in Elderly Patients with Non-Massive Pulmonary Embolism. 2016 , 11, e0155973	20
368	Prevalence and Prognostic Significance of Hyponatremia in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Data from the Akershus Cardiac Examination (ACE) 2 Study. 2016 , 11, e0161232	5
367	Heart failure diagnosis in acute conditions has high agreement with inpatient diagnosis. 2016 , 23, 179-84	8
366	Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction. 2017 , 243, 79-108	4
365	Understanding acute heart failure: pathophysiology and diagnosis. 2016 , 18, G11-G18	25
364	Distribution of soluble suppression of tumorigenicity 2 (sST2), N-terminal pro-brain natriuretic peptide (NT-proBNP), high sensitive troponin I and high-sensitive troponin T in umbilical cord blood. 2016 , 54,	
363	N-Terminal Pro-B-Type Natriuretic Peptide Is Related to Retinal Microvascular Damage: The Rotterdam Study. 2016 , 36, 1698-702	13
362	Role of cardiovascular biomarkers for the assessment of mitral stenosis and its complications. 2016 , 34, 58-62	5
361	Consensus document and recommendations on the use of natriuretic peptides in clinical practice. 2016 , 216, 313-22	12
360	The search for efficient diagnostic and prognostic biomarkers of heart failure. 2016 , 12, 327-37	1
359	Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6 29

358	Change in plasma volume and prognosis in acute decompensated heart failure: an observational cohort study. 2016 , 109, 337-46	17
357	The Inter-rater Reliability of Echocardiographic Diastolic Function Evaluation Among Emergency Physician Sonographers. 2016 , 51, 411-417	6
356	Obesity paradox in heart failure: a heavy matter. <i>ESC Heart Failure</i> , 2016 , 3, 227-234	3.7 45
355	Do Acute Myocardial Infarction and Heart Failure Readmissions Flagged as Potentially Preventable by the 3M Potentially Preventable Readmissions Software Have More Process-of-Care Problems?. 2016 , 9, 532-41	3
354	Cardiac Biomarkers. 2016 ,	1
353	Natriuretic peptide hormones in congestive heart failure: challenges, clinical interpretation and review of studies. 2016 , 71, 417-424	3
352	Factors Associated With Natriuretic Peptide Testing in Patients Presenting to Emergency Departments With Suspected Heart Failure. 2016 , 32, 986.e1-8	5
351	Consensus document and recommendations on the use of natriuretic peptides in clinical practice. 2016 , 216, 313-322	
350	Pharmacologic Trends of Heart Failure. 2016 ,	
349	A Comprehensive Transition of Care Plan for a Patient Admitted with Acute Decompensated Heart Failure. 2016 , 73-124	
348	Diagnosing Acute Heart Failure in the Emergency Department: A Systematic Review and Meta-analysis. 2016 , 23, 223-42	142
347	N-Terminal Pro-Brain Natriuretic Peptide Level is Associated With Severity and Complexity of Coronary Atherosclerosis in Patients With Acute Coronary Syndrome. 2016 , 22, 69-76	4
346	The influence of heart failure co-morbidity on high-sensitivity troponin T levels in COPD exacerbation in a prospective cohort study: data from the Akershus cardiac examination (ACE) 2 study. 2016 , 21, 173-9	4
345	A Test in Context: Critical Evaluation of Natriuretic Peptide Testing in Heart Failure. 2016 , 67, 330-7	35
344	Undiagnosed airflow limitation is common in patients with coronary artery disease and associated with cardiac stress. 2016 , 21, 137-42	9
343	Biomarkers for Heart Failure: An Update for Practitioners of Internal Medicine. 2016 , 129, 560-7	38
342	Preoperative Laboratory Testing. 2016 , 34, 43-58	19
341	Recent advances in point-of-care testing for natriuretic peptides: potential impact on heart failure diagnosis and management. 2016 , 16, 641-50	9

340	The emerging role of galectins in cardiovascular disease. 2016 , 81, 31-41		23
339	Diagnostic utility of contemporary echo and BNP assessment in patients with acute heart failure during early hospitalization. 2016 , 30, 43-48		7
338	Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance. 2016 , 42, 147-63		113
337	How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial. 2016 , 22, 283-93		17
336	Exploring the Potential of Predictive Analytics and Big Data in Emergency Care. 2016 , 67, 227-36		58
335	Diagnostic and Prognostic Utility of Procalcitonin in Patients Presenting to the Emergency Department with Dyspnea. 2016 , 129, 96-104.e7		39
334	Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care?. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017 , 6, 321-328	4.3	21
333	European Society of Cardiology - Acute Cardiovascular Care Association position paper on safe discharge of acute heart failure patients from the emergency department. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017 , 6, 311-320	4.3	42
332	Short Stay Management of Acute Heart Failure. <i>Contemporary Cardiology</i> , 2017 ,		0.1
331	Prognostic prediction in acute heart failure patients with extreme BNP values. 2017 , 22, 715-722		2
330	Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS). <i>European Journal of Heart Failure</i> , 2017 , 19, 739-747	12.3	21
329	Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction. 2017 , 32, 880-892		7
328	Mid-regional pro-adrenomedullin in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study. 2017 , 50, 394-400		7
327	Outpatient Emergencies: Acute Heart Failure. 2017 , 101, 507-519		3
326	Natriuretic Peptides in Older Patients With Heart Failure: A Look Into the Seeds of Time. 2017 , 65, 691-692		
325	The renal and cardiovascular effects of natriuretic peptides. 2017 , 41, 179-185		45
324	Entresto (Sacubitril/Valsartan): Angiotensin Receptor Neprilysin Inhibition for Treating Heart Failure. 2017 , 5, 47-55		
323	Chest Pain. 98-106		

322	Heart Failure. 107-113		
321	Elevated admission N-terminal pro-brain natriuretic peptide level predicts the development of atrial fibrillation in general surgical intensive care unit patients. 2017 , 83, 485-490		5
320	Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. 2017 , 135, e1054-e1091		274
319	Prognostic potential of midregional pro-adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides. <i>European Journal of Heart Failure</i> , 2017 , 19, 1166-1175	12.3	21
318	Natriuretic peptides: degradation, circulating forms, dosages and new therapeutic approaches. 2017 , 75, 259-267		2
317	Heart Failure. 2017 ,		4
316	Cardiac Troponin I and Amino-Terminal Pro B-Type Natriuretic Peptide in Dogs With Stable Chronic Kidney Disease. 2017 , 31, 805-813		11
315	Serum Galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients. 2017 , 58, 350-359		8
314	Role of B-type natriuretic peptide (BNP) in heart failure. 2017 , 16, 3-9		1
313	Biochemistry, Therapeutics, and Biomarker Implications of Neprilysin in Cardiorenal Disease. 2017 , 63, 108-115		32
312	Interpreting Cardiac Biomarkers in the Setting of Chronic Kidney Disease. 2017 , 63, 59-65		45
311	Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study. 2017 , 5, 724-734		49
310	N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. 2017 , 44, 457-465		8
309	Approach to Acute Heart Failure in the Emergency Department. 2017 , 60, 178-186		13
308	Mid-regional pro-adrenomedullin and ST2 in heart failure: Contributions to diagnosis and prognosis. 2017 , 36, 465-472		5
307	[What is the place for biomarkers during acute COPD exacerbations?]. 2017 , 34, 382-394		
306	Rationale and design of the ICON-RELOADED study: International Collaborative of N-terminal pro-B-type Natriuretic Peptide Re-evaluation of Acute Diagnostic Cut-Offs in the Emergency Department. 2017 , 192, 26-37		11
305	Comparative accuracy of NT-proBNP and MR-proANP for the diagnosis of acute heart failure in dyspnoeic patients. <i>ESC Heart Failure</i> , 2017 , 4, 232-240	3.7	17

304	Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction. 2017 , 14, 434-443		13
303	Interpretation of B-type natriuretic peptides in the era of angiotensin receptor-neprilysin inhibitors. 2017 , 36, 881-884		2
302	Managing Heart Failure at Home With Point-of-Care Diagnostics. 2017 , 5, 2800206		10
301	The prognostic value of brain natriuretic peptide (BNP) in non-cardiac patients with sepsis, ultra-long follow-up. 2017 , 42, 117-122		17
300	Mid-regional pro-adrenomedullin and ST2 in heart failure: Contributions to diagnosis and prognosis. 2017 , 36, 465-472		6
299	Cardiorenal acute kidney injury: Epidemiology, presentation, causes, pathophysiology and treatment. <i>International Journal of Cardiology</i> , 2017 , 227, 143-150	3.2	28
298	A Randomized Control Trial Using a Validated Prediction Model for Diagnosing Acute Heart Failure in Undifferentiated Dyspneic Emergency Department Patients-Results of the GASP4Ar Study. 2017 , 23, 145-152		6
297	Hospital Management of Acute Decompensated Heart Failure. <i>American Journal of the Medical Sciences</i> , 2017 , 353, 265-274	2.2	10
296	Novel biomarkers in heart failure: How they change clinical decision?. 2017 , 58, 317-319		3
295	Interpretation of B-type natriuretic peptides in the era of angiotensin receptor-neprilysin inhibitors. 2017 , 36, 881-884		2
294	EACVI appropriateness criteria for the use of transthoracic echocardiography in adults: a report of literature and current practice review. 2017 , 18, 1191-1204		34
293	NT-proBNP test with improved accuracy for the diagnosis of chronic heart failure. 2017 , 96, e9181		15
292	Reference Intervals of Platelets, Lymphocytes and Cardiac Biomarkers in Umbilical Cord Blood. 2017 ,		1
291	Natriuretic Peptides as Biomarkers for Congestive States: The Cardiorenal Divergence. 2017 , 2017, 1454986		8
290	Comparison of prognostic value of N-terminal pro-brain natriuretic peptide in septic and non-septic intensive care patients. 2017 , 13, 418-425		4
289	Prognostic and diagnostic significance of copeptin in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 study. 2017 , 18, 184		15
288	Performance Evaluation of a Point-of-care Test, Samsung LABGEO PA CHF Test, for the Amino-terminal Pro-brain Natriuretic Peptide. 2017 , 7, 135		
287	Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. 2017 , 47, 555-643		44

286	Cardiac Natriuretic Peptides. 2017 , 3-39		1
285	Takotsubo cardiomyopathy: Pathophysiology and role of cardiac biomarkers in differential diagnosis. 2017 , 9, 723-730		27
284	Galcetin - 3 and Cardioresenal Disease. 2017 , 29, 50-58		
283	INTEGRATION OF BIOMARKERS INTO THE PRACTICE OF TREATING PATIENTS WITH HEART FAILURE: THE ROLE OF DETERMINING THE BLOOD LEVEL OF NATRIURETIC PEPTIDES. 2017 , 13, 863-870		
282	Management of chronic heart failure: biomarkers, monitors, and disease management programs. 2014 , 80, 46-54		10
281	Prognostic and diagnostic value of elevated serum concentration of procalcitonin in patients with suspected heart failure. A review and meta-analysis. 2018 , 23, 407-413		4
280	Assessment of left atrial size in addition to focused cardiopulmonary ultrasound improves diagnostic accuracy of acute heart failure in the Emergency Department. 2018 , 35, 785-791		14
279	Sex differences in heart failure. 2018 , 41, 211-216		59
278	Biomarkers for heart failure: small molecules with high clinical relevance. 2018 , 283, 530-543		58
277	Recognizing, Stabilizing, and Managing Children with Heart Failure in the Emergency Department and Other Acute Care Settings. 2018 , 17-32		
276	Evolution of natriuretic peptide biomarkers in heart failure: Implications for clinical care and clinical trials. <i>International Journal of Cardiology</i> , 2018 , 254, 215-221	3.2	17
275	The predictive value of NT-proBNP and hs-TnT for risk of death in cardiac surgical patients. 2018 , 53, 65-71		13
274	Evolving Role of Natriuretic Peptides from Diagnostic Tool to Therapeutic Modality. 2018 , 1067, 109-131		8
273	Signs and symptoms in adult patients with acute dyspnea: a systematic review and meta-analysis. 2018 , 25, 3-11		15
272	Utility of natriuretic peptides to assess and manage patients with heart failure receiving angiotensin receptor blocker/neprilysin inhibitor therapy. 2018 , 130, 299-307		13
271	A cost effectiveness study establishing the impact and accuracy of implementing the NICE guidelines lowering plasma NTproBNP threshold in patients with clinically suspected heart failure at our institution. <i>International Journal of Cardiology</i> , 2018 , 257, 131-136	3.2	0
270	N-Terminal Pro-B-Type Natriuretic Peptide in the Emergency Department: The 1CON-RELOADED Study. 2018 , 71, 1191-1200		72
269	Interpreting the Wide Range of NT-proBNP Concentrations in Clinical Decision Making. 2018 , 71, 1201-1203		10

268	Prehospital triage of patients suffering severe dyspnoea using N-terminal pro-brain natriuretic peptide, the PreBNP trial: a randomised controlled clinical trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018 , 7, 302-310	4.3	4
267	Brain natriuretic peptide levels in middle aged subjects with normal left ventricular function in relation to mild-moderate COPD. 2018 , 12, 1061-1067		
266	Racial Differences in Plasma Levels of N-Terminal Pro-B-Type Natriuretic Peptide and Outcomes: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. 2018 , 3, 11-17		33
265	Natriuretic Peptides in Heart Failure: Atrial and B-type Natriuretic Peptides. 2018 , 14, 13-25		53
264	Soluble ST2 in Heart Failure. 2018 , 14, 41-48		49
263	Information provided by diagnostic and screening tests: improving probabilities. 2018 , 94, 230-235		3
262	Cardiac Biomarkers: What Is and What Can Be. 2018 , 3, 240-244		16
261	Optimal Endpoints of Acute Heart Failure Therapy. 2018 , 25, e465-e474		3
260	OBSOLETE: Biomarkers: Heart Failure. 2018 ,		
259	OBSOLETE: Biomarkers in Heart Failure, Use of. 2018 ,		
258	Cardiorenal Acute Kidney Injury: Epidemiology, Presentation, Causes, Pathophysiology, and Treatment. 2018 , 257-269		1
257	Comparison of the Diagnostic Accuracy of Plasma N-Terminal Pro-Brain Natriuretic Peptide in Patients 80 Years of Age with Heart Failure. <i>American Journal of Cardiology</i> , 2018 , 122, 2075-2079	3	3
256	Biomarkers for acute cardiorenal syndrome. 2018 , 23 Suppl 4, 68-71		11
255	Congestive Heart Failure. 2018 , 411-418.e3		2
254	Adiponectin is valuable in the diagnosis of acute heart failure with renal insufficiency. 2018 , 16, 2725-2734		3
253	NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure. <i>International Journal of Cardiology</i> , 2018 , 271, 324-330	3.2	13
252	Cardiac stress biomarkers after red blood cell transfusion in patients at risk for transfusion-associated circulatory overload: a prospective observational study. 2018 , 58, 2139-2148		5
251	Biomarkers and Heart Failure. 2018 ,		

250	Biomarkers: Heart Failure. 2018 , 315-322	1
249	Biomarkers in Heart Failure, Use of. 2018 , 293-302	
248	The Effect of Left Ventricular Assist Device Therapy on Cardiac Biomarkers: Implications for the Identification of Myocardial Recovery. 2018 , 15, 250-259	8
247	The past, the present, and the future of natriuretic peptides in the diagnosis of heart failure. 2018 , 20, G11-G20	7
246	Sex-Related Aspects of Biomarkers in Cardiac Disease. 2018 , 1065, 545-564	11
245	Using point-of-care ultrasound: Lungs. 2018 , 31, 48-52	4
244	Prognostic Significance of Serum Cysteine-Rich Protein 61 in Patients with Acute Heart Failure. 2018 , 48, 1177-1187	13
243	National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. 2018 , 27, 1123-1208	141
242	Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z. 2018 , 19,	128
241	Diagnostic concordance between NT-proBNP and BNP for suspected heart failure. 2018 , 59, 50-55	20
240	Diagnostic and prognostic properties of procalcitonin in patients with acute dyspnea: Data from the ACE 2 Study. 2018 , 59, 62-68	1
239	Prognostic and diagnostic significance of mid-regional pro-atrial natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 Study. 2018 , 23, 654-663	1
238	Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. 2018 , 12, 2	70
237	Causes of Shortness of Breath in the Acute Patient: A National Study. 2018 , 25, 1227-1234	4
236	Established and Emerging Roles of Biomarkers in Heart Failure. 2018 , 123, 614-629	105
235	Non-natriuretic peptide biomarkers in heart failure with preserved and reduced ejection fraction. 2018 , 12, 783-797	6
234	NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort. <i>Respiratory Medicine</i> , 2018 , 140, 87-93	4.6 9
233	Bedeutung von Biomarkern bei akuter Herzinsuffizienz. 2019 , 22, 148-157	

232	Catestatin in Acutely Decompensated Heart Failure Patients: Insights from the CATSTAT-HF Study. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	15
231	Biomarkers in diagnosing and treatment of acute heart failure. 2019 , 13, 1235-1249		8
230	Cytokines in heart failure. 2019 , 93, 63-113		8
229	2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee. 2019 , 74, 1966-2011		120
228	An update on the use and discovery of prognostic biomarkers in acute decompensated heart failure. 2019 , 19, 1019-1029		5
227	Lung ultrasound integrated with clinical assessment for the diagnosis of acute decompensated heart failure in the emergency department: a randomized controlled trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 754-766	12.3	71
226	B-type natriuretic peptides for the prediction of cardiovascular events and mortality in patients living with HIV: Results from the HIV-HEART study. <i>International Journal of Cardiology</i> , 2019 , 281, 127-132 ^{3,2}		1
225	Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. <i>European Journal of Heart Failure</i> , 2019 , 21, 715-731	12.3	193
224	Clinical Applications of Natriuretic Peptides in Heart Failure and Atrial Fibrillation. 2019 , 20,		12
223	Supplemental thiamine for the treatment of acute heart failure syndrome: a randomized controlled trial. 2019 , 19, 96		5
222	[The relevance of biomarkers in acute heart failure]. 2019 , 60, 587-596		0
221	Implications of Perceived Dyspnea and Global Well-Being Measured by Visual Assessment Scales During Treatment for Acute Decompensated Heart Failure. <i>American Journal of Cardiology</i> , 2019 , 124, 402-408	3	1
220	Biomarkers in the Diagnosis, Management, and Prognostication of Perioperative Right Ventricular Failure in Cardiac Surgery-Are We There Yet?. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	5
219	NT-proBNP incorporated in prediction rule of major peri-operative adverse cardiac event in non-cardiac surgery. 2019 , 17, 127-132		3
218	Cardiac Biomarkers in the Emergency Department: The Role of Soluble ST2 (sST2) in Acute Heart Failure and Acute Coronary Syndrome-There is Meat on the Bone. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	27
217	Biomarkers in Routine Heart Failure Clinical Care. 2019 , 5, 50-56		43
216	Photonic Crystal-Enhanced Fluorescence Imaging Immunoassay for Cardiovascular Disease Biomarker Screening with Machine Learning Analysis. 2019 , 290, 118-124		20
215	Biomarkers and Imaging: Complementary or Subtractive?. 2019 , 15, 321-331		9

214	Utility of Cardiac Biomarkers in the Setting of Kidney Disease. 2019 , 141, 227-235		17
213	NT-proBNP in the Prognosis of Death or Need for Renal Replacement Therapy in Patients with Stage 3-5 Chronic Kidney Disease. 2019 , 9, 125-134		3
212	NT-ProBNP Predicts Total Mortality, Emergency Department Visits, Hospitalization, Intensive-Care Unit Admission, and Cardiovascular Events in Hemodialysis Patients. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	3
211	Cardiac Biomarkers Predict Long-term Survival After Cardiac Surgery. 2019 , 108, 1776-1782		6
210	Towards Point-of-Care Heart Failure Diagnostic Platforms: BNP and NT-proBNP Biosensors. 2019 , 19,		16
209	Evolving Use of Biomarkers in the Management of Heart Failure. 2019 , 27, 153-159		12
208	The Increasing Perioperative Impact of Natriuretic Peptides on Cardiovascular Outcomes. 2019 , 33, 2065-2069		
207	Breathprinting-Based Diagnosis, Selected Case Study: Nonneoplastic Chronic Diseases. 2019 , 95-120		1
206	NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF. 2019 , 7, 158-168		26
205	Management of Fluid Overload in Cardiorenal Patients. 2019 , 825-835.e2		
204	Prospective evaluation and long-term follow-up of patients referred to secondary care based upon natriuretic peptide levels in primary care. 2019 , 5, 218-224		1
203	Inflammatory Biomarkers and Clinical Judgment in the Emergency Diagnosis of Urgent Abdominal Pain. 2019 , 65, 302-312		3
202	Inflammatory Markers and Novel Risk Factors. <i>Contemporary Cardiology</i> , 2019 , 87-98	0.1	
201	Transfusion-associated circulatory overload-a systematic review of diagnostic biomarkers. 2019 , 59, 795-805		15
200	Post-discharge rise in BNP and rehospitalization for heart failure. 2019 , 44, 450-454		3
199	Diagnostic value of novel biomarkers for heart failure : A meta-analysis. 2020 , 45, 65-78		10
198	Diagnostic value of MR-proANP for heart failure in patients with acute dyspnea:a meta-analysis. 2020 , 75, 68-74		2
197	Inpatient management of acute decompensated heart failure. 2020 , 96, 33-42		3

- 196 Can Biomarkers Provide Right Ventricular-Specific Prognostication in the Perioperative Setting?. **2020**, 26, 776-780 1
- 195 Biomarkers and Precision Medicine in Heart Failure. **2020**, 449-466.e3
- 194 Prognostic significance of oscillatory ventilation at rest in patients with advanced heart failure undergoing cardiopulmonary exercise testing. *International Journal of Cardiology*, **2020**, 301, 142-146 3.2 2
- 193 Independent Impact of Gynoid Fat Distribution and Free Testosterone on Circulating Levels of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) in Humans. *Journal of Clinical Medicine*, **2019**, 9, 5.1 7
- 192 Coronary Sinus Neuropeptide Y Levels and Adverse Outcomes in Patients With Stable Chronic Heart Failure. **2020**, 5, 318-325 20
- 191 Péptidos natriuréticos en la detección de disfunción ventricular izquierda en población de alto riesgo. Metaanálisis de pruebas diagnósticas. **2020**, 27, 545-556
- 190 Heat shock protein 27 as a predictor of prognosis in patients admitted to hospital with acute COPD exacerbation. **2020**, 25, 141-149 3
- 189 Galectin-3 and acute heart failure: genetic polymorphisms, plasma level, myocardial fibrosis and 1-year outcomes. **2020**, 14, 943-954 1
- 188 Conceptualizations of clinical decision-making: a scoping review in geriatric emergency medicine. **2020**, 20, 73 2
- 187 Diagnostic and prognostic considerations for use of natriuretic peptides in obese patients with heart failure. **2020**, 63, 649-655 4
- 186 Red Blood Cell Distribution Width, Neutrophil-to-Lymphocyte Ratio, and In-Hospital Mortality in Dyspneic Patients Admitted to the Emergency Department. **2020**, 2020, 8839506 1
- 185 Biomarkers for coronary artery disease and heart failure. **2020**, 519-543 1
- 184 Competitive ELISA for N-terminal pro-brain natriuretic peptide (NT-proBNP) determination in human plasma. **2020**, 145, 6719-6727 4
- 183 Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide and Glomerular Filtration Rate in Patients With Acute Heart Failure. **2020**, 7, 123 3
- 182 The inflammatory markers sST2, HSP27 and hsCRP as a prognostic biomarker panel in chronic heart failure patients. **2020**, 510, 507-514 5
- 181 Comparison of probiotic yogurt and ordinary yogurt consumption on serum Pentraxin3, NT-proBNP, oxLDL, and ApoB100 in patients with chronic heart failure: a randomized, triple-blind, controlled trial. **2020**, 11, 10000-10010 4
- 180 BNP and NT-proBNP Interpretation in the Neprilysin Inhibitor Era. **2020**, 22, 150 4
- 179 Cardiovascular Biomarkers and Imaging in Older Adults: JACC Council Perspectives. **2020**, 76, 1577-1594 7

178	Validation of radiofrequency determined lung fluid using thoracic CT: Findings in acute decompensated heart failure patients. 2020 , 30, 100645		1
177	The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 1595-1604	3.7	7
176	Clinical and echocardiographic characteristics of individuals aged 75/76 years old with screening-detected elevated NT-proBNP levels. <i>Open Heart</i> , 2020 , 7, e001200	3	1
175	cBIN1 Score (CS) Identifies Ambulatory HFrEF Patients and Predicts Cardiovascular Events. <i>Frontiers in Physiology</i> , 2020 , 11, 503	4.6	5
174	Clinical prediction model construction and evaluation: a challenge for clinical researchers. 2020 , 8, 74		
173	Circulating Forms of B-Type Natriuretic Peptide in Very Preterm Infants. 2020 , 5, 506-515		0
172	Acute heart failure. 2020 , 6, 16		70
171	Elevated plasma phenylalanine predicts mortality in critical patients with heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 2884-2893	3.7	9
170	The diagnostic accuracy of lung auscultation in adult patients with acute pulmonary pathologies: a meta-analysis. 2020 , 10, 7347		18
169	N-terminal pro-B-type natriuretic peptide is a specific predictor of appropriate device therapies in patients with primary prevention implantable cardioverter-defibrillators. 2021 , 18, 71-78		2
168	N-terminal pro BNP and galectin-3 are prognostic biomarkers of acute heart failure in sub-Saharan Africa: lessons from the BAHEF trial. <i>ESC Heart Failure</i> , 2021 , 8, 74-84	3.7	2
167	Elevated high-sensitivity troponin T levels at 1-year follow-up are associated with increased long-term mortality after TAVR. <i>Clinical Research in Cardiology</i> , 2021 , 110, 421-428	6.1	0
166	Cardiac biomarkers and association with subsequent cardiomyopathy and mortality among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort. 2021 , 127, 458-466		3
165	Biomarkers in Acute Heart Failure: Diagnosis, Prognosis, and Treatment. 2021 , 3, 81		3
164	Impact of congestive heart failure and role of cardiac biomarkers in COVID-19 patients: A systematic review and meta-analysis. 2021 , 73, 91-98		11
163	[The use of diuretics in chronic heart failure. Position paper of the Russian Heart Failure Society]. 2021 , 60, 13-47		5
162	Biochemical or clinical heart failure, not so simple. <i>European Journal of Heart Failure</i> , 2021 , 23, 465-467	12.3	0
161	Circulating MicroRNA-210 Concentrations in Patients with Acute Heart Failure: Data from the Akershus Cardiac Examination 2 Study. 2021 , 67, 889-898		1

160	ROLE OF N-TERMINAL PRO-B-TYPE NATRIURETIC PEPTIDE (NT-PROBNP) AS A PROGNOSTIC MARKER FOR THE PATIENTS OF ACUTE BREATHLESSNESS IN THE EMERGENCY DEPARTMENT (ED). 2021 , 2-6		
159	Deep Learning Predicts Patterns of Cardiotoxicity in a High-Content Screen Using Induced Pluripotent Stem Cell-Derived Cardiomyocytes.		0
158	Relationship between the face scale for rating of perceived exertion and physiological parameters in older adults and patients with atrial fibrillation. 2021 , 9, e14759		0
157	Biomarkers for the diagnosis and management of heart failure. 2021 , 1		11
156	Prediction of troponin I and N-terminal pro-brain natriuretic peptide levels in acute carbon monoxide poisoning using advanced electrocardiogram analysis, Alexandria, Egypt. 2021 , 28, 48754-48766		0
155	Economic Evaluation of an N-terminal Pro B-type Natriuretic Peptide-Supported Diagnostic Strategy Among Dyspneic Patients Suspected of Acute Heart Failure in the Emergency Department. <i>American Journal of Cardiology</i> , 2021 , 147, 61-69	3	1
154	Epitranscriptomics of Ischemic Heart Disease-The IHD-EPITRAN Study Design and Objectives. 2021 , 22,		6
153	Strong and Direct Correlation in Heart Failure Between B-Lines and NT-ProBNP Levels.		
152	The 'Peptide for Life' Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe. <i>European Journal of Heart Failure</i> , 2021 , 23, 1432-1436	12.3	0
151	Elevated plasma levels of NT-proBNP in ambulatory patients with peripheral arterial disease. 2021 , 16, e0253792		
150	The Utility of N-Terminal Pro-Brain Natriuretic Peptide as an Adjunct Diagnostic Tool for Acute Heart Failure in Acute Dyspneic Patients Coming to the Emergency Department: A Retrospective Review of Our Early Experience. 2021 , 28, 146-152		
149	Deep learning detects cardiotoxicity in a high-content screen with induced pluripotent stem cell-derived cardiomyocytes. 2021 , 10,		4
148	High-sensitivity cardiac troponin T determines all-cause mortality in cancer patients: a single-centre cohort study. <i>ESC Heart Failure</i> , 2021 , 8, 3709-3719	3.7	7
147	Biomarkers in Acute Heart Failure Syndromes: An Update. 2021 ,		0
146	NT-proBNP Response to Heart Failure Therapies: An Imperfect Surrogate. 2021 , 78, 1333-1336		1
145	The Utility of Circulating and Imaging Biomarkers Alone and in Combination in Heart Failure. 2021 , 17, e160721193557		0
144	Clinical Translation of Discoveries in Cardiomyocyte Biology. 2021 , 315-340		
143	Use of Natriuretic Peptides in the Emergency Department and the ICU. 2009 , 523-530		0

142	Consensus document: management of heart failure in type 2 diabetes mellitus. 2021 , 26, 1037-1062		2
141	Vasoactive Molecules and the Kidney. 2012 , 384-420		2
140	Clinical Assessment of Heart Failure. 2012 , 505-516		3
139	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. 2020 , 8,		66
138	Racial differences in the association of NT-proBNP with risk of incident heart failure in REGARDS. 2019 , 5,		7
137	Utility of NT-proBNP for identifying LV failure in patients with acute exacerbation of chronic bronchitis. 2013 , 8, e52553		5
136	The effects of super-flux (high performance) dialyzer on plasma glycosylated pro-B-type natriuretic peptide (proBNP) and glycosylated N-Terminal proBNP in end-stage renal disease patients on dialysis. 2014 , 9, e92314		9
135	ROLE OF PLASMA N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE (NT-PRO-BNP), A DIAGNOSTIC AND PROGNOSTIC BIOMARKER OF ACUTE DYSPNOEA OF CARDIAC DISEASES. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2017 , 6, 7030-7035	0.1	1
134	Diagnostic and Prognostic Value of N-Terminal Brain Natriuretic Peptide in Patients of Heart Failure. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2020 , 9, 2176-2180	0.1	1
133	Plasma Interleukin-6 Level is Associated with NT-proBNP Level and Predicts Short- and Long Term Mortality in Patients with Acute Heart Failure. 2010 , 53, 225-228		13
132	Recent Patient Characteristics and Medications at Admission and Discharge in Hospitalized Patients With Heart Failure. 2016 , 8, 97-104		3
131	The Change in Body Weight During Hospitalization Predicts Mortality in Patients With Acute Decompensated Heart Failure. 2017 , 9, 200-206		2
130	Hypothyroidism and non-cardiogenic pulmonary edema: are we missing something here?. 2015 , 2015, 150014		2
129	Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction. 2020 , 6, 1-7		1
128	[B-type natriuretic hormone--diagnostic and prognostic cardiovascular biomarker]. 2007 , 148, 217-21		0
127	. 2018 , 58, 42-72		11
126	CLINICAL VALUE OF BLOOD BIOMARKERS IN PATIENTS WITH CHRONIC HEART FAILURE. 2018 , 8, 333-345		10
125	Suggestions for designing studies investigating diagnostic accuracy of biomarkers. 2019 , 7, 788		10

124	Therapeutic Progress and Knowledge Basis on the Natriuretic Peptide System in Heart Failure. 2019 , 19, 1850-1866	3
123	Relationship of preoperative NT-pro BNP with clinical, perioperative and prognostic markers in cardiac surgery: Preliminary study results. 4,	1
122	Identifying Cardiac Diseases using Cardiac Biomarkers in Rhesus Macaques (). 2020 , 70, 348-357	2
121	High circulating N-terminal pro-brain natriuretic peptide and tumor necrosis factor-alpha in mixed cryoglobulinemia. 2009 , 15, 5074-9	2
120	[Diagnostic accuracy for heart failure Data from the Akershus Cardiac Examination 2 Study]. 2015 , 135, 1738-44	6
119	Combination of high-sensitivity C-reactive protein with logistic EuroSCORE improves risk stratification in patients undergoing TAVI. 2018 , 14, 629-636	2
118	Prognostic value of increased carbohydrate antigen in patients with heart failure. 2014 , 6, 205-12	6
117	Comparison of NT-proBNP levels in hemodialysis versus peritoneal dialysis patients. 2013 , 157, 325-30	3
116	The time-course changes of NT-proBNP and tissue Doppler indices in patients undergoing mitral valve replacement. 2012 , 23, 200-5	2
115	Galectin-3: A Link between Myocardial and Arterial Stiffening in Patients with Acute Decompensated Heart Failure?. 2016 , 106, 121-9	5
114	Exhaled breath analysis in the differentiation of pneumonia from acute pulmonary oedema. 2015 , 3, 3	1
113	Factors associated with baseline and serial changes in circulating NT-proBNP and high-sensitivity cardiac troponin T in a population-based cohort (Dallas Heart Study). 2021 , 15, 1487-1498	1
112	Biomarkers in the management of acute heart failure: state of the art and role in COVID-19 era. <i>ESC Heart Failure</i> , 2021 ,	3-7 4
111	A Novel Paradigm Based on ST2 and Its Contribution towards a Multimarker Approach in the Diagnosis and Prognosis of Heart Failure: A Prospective Study during the Pandemic Storm. <i>Life</i> , 2021 , 11,	3 5
110	Combination of D-dimer and amino-terminal pro-B-type natriuretic Peptide testing for the evaluation of dyspneic patients with and without acute pulmonary embolism. 2006 , 130, 1326-9	10
109	Molecular Analysis of Heart Failure and Remodeling. 2007 , 441-469	
108	The impact of amino-terminal pro-brain natriuretic peptide testing on hospital length of stay and morbidity in patients with acute decompensated heart failure. 2007 , 131, 473-6	10
107	B-Type Natriuretic Peptide Testing in the Emergency Room and Intensive Care Unit for the Patient with Acute Heart Failure. 2008 , 468-474	

- 106 Use of natriuretic peptide assay in dyspnea. **2008**, 105, 95-100 3
- 105 The ability of heart failure specialists to accurately predict NT-proBNP levels based on clinical assessment and a previous NT-proBNP measurement. **2008**, 2, 36-40
- 104 Amino-terminal pro-brain natriuretic peptid in prediction of left ventricular ejection fraction. **2008**, 8, 282-6
- 103 Use of Natriuretic Peptides in the Emergency Department and the ICU. **2009**, 523-530
- 102 Biomarkers in predicting mortality and treatment in hemodialysis patients. **2009**, 1,
- 101 Hemodynamic Monitoring in Heart Failure. **2010**, 119-154
- 100 OmicsApplication in Heart Failure: Novel Diagnostic and Prognostic Markers to Understand Pathophysiology and Find New Therapies. **2010**, 365-376
- 99 Heart Failure. **2010**, 1036-1053
- 98 Measurement of N-terminal pro-B-type natriuretic peptide(NT-proBNP)in hemodialysis patients-Examination by electrocardiogram-. **2010**, 43, 633-640
- 97 Diagnosis of Heart Failure: Evidence-Based Perspective. **2010**, 353-363
- 96 Natriuretic Peptides. **2010**, 309-318 1
- 95 Characteristics of patients on the waiting list for heart transplantation. **2010**, 52, 149-153
- 94 Inflammatory Markers and Novel Risk Factors. **2011**, 107-123
- 93 Validity of Amino Terminal pro-Brain Natiuretic Peptide in a Medically Complex Elderly Population. **2011**, 3, 156-63 0
- 92 Congestive Heart Failure. **2012**, 281-324
- 91 Volume Assessment in the Emergency Department. *Contemporary Cardiology*, **2012**, 113-124 0.1
- 90 B-Type Natriuretic Peptide: Beyond Diagnostic Applications. **2012**, 67-77 5
- 89 Cardiac Function. **2012**, 1457-1522 1

88 Diagnostic and Prognostic Biomarkers in Emergency Department Heart Failure. *Contemporary Cardiology*, **2012**, 125-139 0.1

87 Disorders of Sodium Balance. **2012**, 464-539

86 Management of acute heart failure-Is there a paradigm shift around the corner?. *World Journal of Cardiovascular Diseases*, **2013**, 03, 1-7 0

85 Basic Statistics. **2014**, 224-237

84 Using NT-proBNP to Detect Chronic Heart Failure in Elderly Patients with Chronic Obstructive Pulmonary Disease. *ISRN Family Medicine*, **2013**, 2013, 273864 2

83 Biomarkers and Optimal Management of Heart Failure in the Aging Population. **2014**, 135-146

82 Acute heart failure. **2014**, 271-288.e5

81 Natriuretic Peptides for Diagnosis, Prognosis, and Management of Heart Failure. **2014**, 1-21

80 Markers and Correlates of Right Ventricular Function with Computed Tomography, Echocardiography, and Magnetic Resonance. **2015**, 1-38

79 Natriuretic Peptides for Diagnosis, Prognosis, and Management of Heart Failure. *Biomarkers in Disease*, **2015**, 731-756

78 Volume Assessment and Management: Medical and Device Therapies. **2016**, 125-163

77 Biomarkers in Heart Failure with Preserved Ejection Fraction. **2016**, 357-365

76 Caveats Using Natriuretic Peptide Levels. **2016**, 227-236

75 Markers and Correlates of Right Ventricular Function with Computed Tomography, Echocardiography, and Magnetic Resonance. **2016**, 1183-1219

74 Volume Assessment in Heart Failure. *Contemporary Cardiology*, **2017**, 117-128 0.1

73 Diagnostic and Prognostic Biomarkers in Emergency Department Heart Failure. *Contemporary Cardiology*, **2017**, 145-163 0.1

72 Acute Decompensated Heart Failure: Presentation, Physical Exam, and Laboratory Evaluation. **2017**, 171-193

71 Acute Heart Failure. **2017**, 105-117

70	Acute Decompensated Heart Failure: Treatment Guidelines. 2017 , 195-218		0
69	A CLINICAL STUDY OF N-TERMINAL PRO-BNP LEVELS IN CONGESTIVE HEART FAILURE. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2017 , 6, 1000-1004	0.1	
68	Biomarkers: New Horizon for Heart Failure Practice. 2018 , 17-38		
67	The role of galectin-3 in the diagnosis and control of the effectiveness of pharmacotherapy of chronic heart failure. <i>Cardiosomatics</i> , 2017 , 8, 5-10	0.4	1
66	Photonic Crystal-Enhanced Fluorescence Imaging of Cardiovascular Biomarker with Machine Learning Analysis. 2019 ,		
65	An interesting hormon and interesting disease: hyperprolactinemia and prolactinoma. <i>Ortadoğu Tıp Dergisi</i> , 2019 , 11, 561-576	0.1	
64	The impact of renal function on the prognostic value of N-terminal pro-B-type natriuretic peptide in patients with coronary artery disease. <i>Cardiology Journal</i> , 2019 , 26, 696-703	1.4	1
63	Dyspnea. 2020 , 15-26		
62	Clearing the Congestion: Chest Radiography and BNP to Rule-out Congestive Heart Failure. <i>Journal of Thoracic Imaging</i> , 2021 ,	5.6	0
61	Diagnostic biomarkers of dilated cardiomyopathy. <i>Immunobiology</i> , 2021 , 226, 152153	3.4	0
60	Impact of Congestive Heart Failure and Role of Cardiac Biomarkers in COVID-19 patients: A Systematic Review and Meta-Analysis.		
59	Les marqueurs biologiques dans ICA. 2006 , 101-114		
58	Study on the Relationship between Pro-Brain Natriuretic Peptide and Routine Blood Test Factors at a General Hospital in Gyeonggi-do. <i>Korean Journal of Clinical Laboratory Science</i> , 2020 , 52, 172-180	0.4	
57	Novel Biomarkers of Acute Cardiorenal Disease. 2021 , 207-225		
56	Institute for Quality in Laboratory Medicine series--controversies in laboratory medicine: insights into B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide measurements. <i>MedGenMed: Medscape General Medicine</i> , 2006 , 8, 62		
55	National Academy of Clinical Biochemistry (NACB) laboratory medicine guidelines on the clinical utilization and analytical issues for cardiac biomarker testing in heart failure. <i>Clinical Biochemist Reviews</i> , 2008 , 29, 107-11	7.3	1
54	The Importance of Amino-terminal pro-Brain Natriuretic Peptide Testing in Clinical Cardiology. <i>Biomarker Insights</i> , 2007 , 1, 143-55	3.5	
53	Integrating PoCT into Clinical Care. <i>Clinical Biochemist Reviews</i> , 2010 , 31, 99-104	7.3	8

52	Can NT-proBNP be used as a criterion for heart failure hospitalization in emergency room?. <i>Journal of Research in Medical Sciences</i> , 2011 , 16, 1564-71	1.6	6
51	Short-term prognostic factors in the patients after acute heart failure. <i>International Journal of Clinical and Experimental Medicine</i> , 2015 , 8, 1515-20		2
50	Biomarkers Beyond the Natriuretic Peptides for Chronic Heart Failure: Galectin-3 and Soluble ST2. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2012 , 23, 98-102	2.4	2
49	Cardiovascular risk prediction in the elderly. <i>Journal of Geriatric Cardiology</i> , 2019 , 16, 414-420	1.7	1
48	Neurohumoral, cardiac and inflammatory markers in the evaluation of heart failure severity and progression. <i>Journal of Geriatric Cardiology</i> , 2021 , 18, 47-66	1.7	1
47	Heart failure biomarkers BNP and NT-proBNP detection using optical labels. <i>TrAC - Trends in Analytical Chemistry</i> , 2022 , 146, 116477	14.6	1
46	Insuffisance cardiaque et peptide natriurétique de type B (BNP) Rappel de notions fondamentales. <i>Bio Tribune Magazine</i> , 2007 , 22, 19-20		
45	Intérêt du dosage des peptides natriurétiques en urgence dans la dyspnée aiguë <i>Bio Tribune Magazine</i> , 2007 , 22, 25-29		
44	BNP und NT-proBNP: Zwei kardiale Marker werden überwacht		1
43	Natriuretic Peptide-Based Inclusion Criteria in Heart Failure with Preserved Ejection Fraction Clinical Trials: Insights from PARAGON-HF.. <i>European Journal of Heart Failure</i> , 2022 ,	12.3	0
42	A New Biomarker Tool for Risk Stratification in " Acute Heart Failure (OROME).. <i>Frontiers in Physiology</i> , 2021 , 12, 736245	4.6	0
41	Prognostic value of NT-proBNP in Patients with Successful PCI for ACS and Normal Left Ventricular Ejection Fraction: NT-proBNP in ACS with Normal LVEF.. <i>American Journal of the Medical Sciences</i> , 2022 ,	2.2	1
40	Biomarker Development in Cardiology: Reviewing the Past to Inform the Future.. <i>Cells</i> , 2022 , 11,	7.9	0
39	Role of biomarkers in the heart failure clinic. <i>Kosin Medical Journal</i> , 2022 , 37, 4-17	0.1	2
38	Coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients-a large monocenter cohort study.. <i>Clinical Research in Cardiology</i> , 2022 , 1	6.1	
37	NT-proBNP and sRAGE levels in early rheumatoid arthritis.. <i>Scandinavian Journal of Rheumatology</i> , 2022 , 1-7	1.9	1
36	A novel electrochemiluminescent immunosensor for the detection of NT-proBNP based on a Au/ZIF-67 nanocomposite. <i>Journal of Electroanalytical Chemistry</i> , 2022 , 912, 116260	4.1	2
35	Heart failure in patients with COPD exacerbations: Looking below the tip of the iceberg.. <i>Respiratory Medicine</i> , 2022 , 196, 106800	4.6	0

34	Assessment of the impact of different N terminal pro brain natriuretic peptide thresholds on echocardiography services. <i>ESC Heart Failure</i> , 2021 ,	3.7	1
33	Low-Level Elevations of Procalcitonin Are Associated with Increased Mortality in Acute Heart Failure Patients, Independent of Concomitant Infection.. <i>Life</i> , 2021 , 11,	3	
32	Effects of Sildenafil on spirometric pulmonary function parameters, pulmonary artery systolic pressure and BNP levels in patients with chronic obstructive pulmonary disease and erectile dysfunction. <i>IP Indian Journal of Immunology and Respiratory Medicine</i> , 2021 , 6, 226-233	1	
31	Use of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in the emergency department.. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022 ,	4.3	0
30	Data_Sheet_1.PDF. 2020 ,		
29	Prognostic value of cardiac biomarkers and National Early Warning Score 2 in acute dyspnoea.. <i>Open Heart</i> , 2022 , 9,	3	0
28	Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.. <i>Journal of Geriatric Cardiology</i> , 2021 , 18, 908-951	1.7	2
27	Minimally Invasive and Non-Invasive Sensor Technologies for Predicting Heart Failure. 2022 , 109-138		
26	The Prognostic Value of Natriuretic Peptides in Stable Patients with Suspected Acute Myocarditis: A Retrospective Study.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	
25	Pediatric Myocarditis: What Have We Learnt So Far?. <i>Journal of Cardiovascular Development and Disease</i> , 2022 , 9, 143	4.2	1
24	Efficacy and Dosage Pattern of Sacubitril/Valsartan in Chinese Heart Failure with Reduced Ejection Fraction Patients.. <i>Journal of Cardiovascular Translational Research</i> , 2022 , 1	3.3	0
23	Cardiac troponin T and NT-proBNP for detecting myocardial ischemia in suspected chronic coronary syndrome.. <i>International Journal of Cardiology</i> , 2022 ,	3.2	0
22	The Effects of Exercise Training on Cardiopulmonary Exercise Testing and Cardiac Biomarkers in Adult Patients with Hypoplastic Left Heart Syndrome and Fontan Circulation. <i>Journal of Cardiovascular Development and Disease</i> , 2022 , 9, 171	4.2	1
21	Multidimensional Approach of Heart Failure Diagnosis and Prognostication Utilizing Cardiac Imaging with Biomarkers. <i>Diagnostics</i> , 2022 , 12, 1366	3.8	1
20	Brain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure. <i>Journal of Clinical Medicine</i> , 2022 , 11, 3192	5.1	0
19	Biomarkers in heart failure: Relevance in the clinical practice. <i>International Journal of Cardiology</i> , 2022 ,	3.2	1
18	Diurnal Variations in Natriuretic Peptide Levels: Clinical Implications for the Diagnosis of Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2022 , 15,	7.6	0
17	Shenmai Injection Improves Hypertensive Heart Failure by Inhibiting Myocardial Fibrosis via TGF- β 1/Smad Pathway Regulation. <i>Chinese Journal of Integrative Medicine</i> ,	2.9	0

16	Clinical Effect of Obesity on NT-proBNP Cut-off Concentrations for the Diagnosis of Acute Heart Failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1233-1241.	12,3	1
15	Phenotypic screening with deep learning identifies HDAC6 inhibitors as cardioprotective in a BAG3 mouse model of dilated cardiomyopathy. 2022 , 14,		0
14	Cardiovascular-derived therapeutic peptidomimetics in cardiovascular disease. 2022 , 579-614		0
13	Prognostic value and clinical utility of NT-proBNP in acute emergency medical admissions.		0
12	CLINICAL SIGNIFICANCE OF NATRIURETIC PEPTIDES (review). 2022 , 9, 5-13		0
11	Diagnostic usefulness of NT-proBNP in asymptomatic left ventricular dysfunction in black hypertensive patients. 2021 , 18, 44		0
10	The Role of Biomarkers in Heart Failure with Preserved Ejection Fraction. 2022 , 2, 281-289		0
9	One-Step Photochemical Immobilization of Aptamer on Graphene for Label-Free Detection of NT-proBNP. 2022 , 12, 1071		1
8	Construction and evaluation of nomogram model for individualized prediction of risk of major adverse cardiovascular events during hospitalization after percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. 9,		0
7	Circulating Biomarkers of Cardiopulmonary Disturbances in COVID-19. 2023 , 99-112		0
6	Age affects the diagnostic accuracy of serum N-terminal pro-B-type natriuretic peptide for heart failure in patients with pleural effusion. 2023 ,		0
5	Misconceptions and Facts about Heart Failure with Reduced Ejection Fraction. 2023 ,		0
4	N-terminal proB-type natriuretic peptide levels in normotensive and hypertensive dogs with myxomatous mitral valve disease stage B. 2023 , 76,		0
3	Serum Catestatin Concentrations Are Increased in Patients with Atrial Fibrillation. 2023 , 10, 85		0
2	Novel Oxidative Stress Biomarkers with Risk Prognosis Values in Heart Failure. 2023 , 11, 917		0
1	Congestive Heart Failure. 2013 , 476-486.e1		0